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ABSTRACT 
 
Nitric oxide (NO) is a vital gasotransmitter, involved in a plethora of signaling 
pathways. With bioavailable NO stored as S-nitrosoglutathione (GSNO), its enzymatic 
degradation by S-nitrosoglutathione reductase (GSNOR) has a large impact on cellular 
SNO levels. This thesis consists of two components: chapter one explores the production 
of NO generating particles, that use chitosan as a matrix for a copper catalyst. Chapter two 
reports the discovery into a new regulatory domain on the GSNOR enzyme.  
In chapter one, we have developed a novel technology capable of generating NO, 
in the form of NO-releasing copper-chitosan particles (Cu-chito). These particles were 
successfully tested in their release of authentic NO: the maximum rate of production was 
1.40 nmol/min/g. The Cu-chito particle treatments were analysed using scratch assays. In 
comparison to control groups: Cu-chito particles, which provide bioactive NO, displayed 
130% of cells in the wound, while treatments with supplemented glucose displayed 152%. 
This supports the hypothesis that glucose aids to regenerate active copper in the catalytic 
cycle of NO production. Matrix metalloproteinases (MMP-2 and -9) were chosen as an 
intracellular NO target. The activity MMP was investigated: displayed an increase of 60% 
after Cu-chito treatments. The NO treatments provide a lasting effect on a cellular level.  
Presented in chapter two is the discovery of a new regulatory domain on GSNOR: 
an allosteric binding domain. A sigmoidal deviation in GSNOR kinetics indicated positive 
cooperativity for GSNO binding. Molecular docking (MD) simulations indicates the 
location a putative allosteric site at the amino acid residues Gly321, Lys323, Asn185, and 
Lys188. To further these studies hydrogen / deuterium exchange (HDX) mass spectrometry 
(MS) experiments were performed. With a two second HDX reaction, the residues Gly321, 
Lys323, and Lys188 displayed a decrease in deuterium uptake of 1.4%, 1.4%, and 0.4%, 
after the incorporation of GSNO. These results strongly support the existence of a 
secondary binding domain of substrate GSNO that contributes to its mechanism of action.  
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CHAPTER 1: Nitric Oxide Generating Copper-Chitosan 
Particles 
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1.1 Chapter Summary  
Nitric oxide (NO) is a signaling molecule that plays many roles during infection, 
inflammation, and wound healing processes. Due to NO’s role in wound repair, we have 
developed a novel NO generation system based on copper-chitosan complexes that can be 
used for the topical generation of NO. Chitosan, a biocompatible polymer, chelates copper 
ions. Copper in the +1 state can reduce nitrite (NO2
–) and convert it into NO. With glucose, 
a reducing sugar, present in the system, Cu+2 can be returned to Cu+1 to complete the 
catalytic cycle. Copper-chitosan milli- and micro- sized particles were produced using 
microfluidic techniques. Copper-chitosan milli-particles (Cu-chito) did produce nitric 
oxide (NO). The maximum rates of NO production were ~ 1.40 nmol/min/g (Cu-chito) and 
1.08 nmol/min/g (Cu-chito + glucose). The milli-particles were tested with ARPE-19 cell 
lines in scratch assays, to mimic an in vitro model for wound healing. Cu-chito particle 
treatments with nitrite showed 130% new cells in the wound in comparison to chitosan 
milli-particles not containing copper. Furthermore, Cu-chito treatments of nitrite + glucose 
showed 152% new cells in the wound in comparison to control groups, and 118% in 
comparison to Cu-chito with nitrite alone. The activity of intracellular NO target, matrix 
metalloproteinases (MMP-2 and -9), were shown to increase by 60% after 48 hours of Cu-
chito ± glucose treatments. 
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1.2 Introduction 
This chapter focuses on the development of a nitric oxide (NO) releasing 
technology for the desired application relating to wound healing and other similar medical 
or biological fields. In order to do this, the physiological relevance and implications of NO 
and other components of the technology must first be described. 
1.2.1 Gasotransmitters 
Gasotransmitters is a term used to describe a group of small gaseous signaling 
molecules consisting of nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide 
(H2S). As a group, gasotransmitters have several interesting properties. They are 
endogenously produced molecules that have significant roles as physiologic mediators in 
the cardiovascular (NO, CO, H2S), immune (NO, CO), and nervous systems (NO, H2S), 
while also existing as toxic gasses.1-3 They have high lipid solubilities, can freely pass 
through cellular membranes and have specific targets; including the metal centers of 
metalloproteins, such as guanylyl cyclase.1-2 For example, the main targets of NO, and 
other reactive nitrogen species (RNS), include metal centers and thiols.3 
The ability to penetrate the cellular membrane is just one property that distinguishes 
gasotransmitters from other, more classical signaling molecules, which could require other 
mechanisms, such as binding to plasma membrane receptors in order to reach their targets.1-
2 Since gaseous molecules are not easily stored (i.e. in vesicles), they are produced as 
required and diffused out. In turn, the robust reactivity of NO and H2S relates to the 
requirement of being subjected to regulatory systems. For example, both molecules will 
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readily react with the cysteine thiol of glutathione, which could yield problematic results 
if that is not the intended destination.2 The robust action of NO and H2S is countered by 
the body’s ability to biochemically detox them; they are readily metabolized by 
cytochrome oxidases (a group of metalloproteins).3-4 In the instance of NO, regulation is 
performed by the control of nitic oxide synthases (NOS), the group of enzymes responsible 
for its biosynthesis. NO can reach its target by the binding of NOS to the protein target, or 
with the aid of scaffolding proteins.2 
As it stands, the reaction of NO and H2S with glutathione does a sufficient job of 
visualizing the effects that are typical of gasotransmitters; by chemically modifying 
intracellular proteins. In contrast to classical messenger molecules mode of action being 
amplifying signaling cascades. The chemical reactions of glutathione (GSH) reacting with 
NO and H2S are shown in Figure 1.2.1a.  
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Figure 1.2.1a: Glutathione (GSH) reacting with the gasotransmitters NO and H2S. 
Producing S-nitrosoglutathione (GSNO) and oxidized glutathione (GSSH), respectively.  
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1.2.2 Nitric Oxide, the First Gasotransmitter 
Nitric oxide (NO), the gaseous radical shown in Figure 1.2.2a, was the first 
identified gasotransmitter. The molecule itself was discovered in 1772 by Joseph Priestley. 
In the late 1980’s there were breakthroughs in regards to its biological role. The research 
group led by Dr. Louis J. Ignarro discovered that NO was the endothelium-derived relaxing 
factor (EDRF). This led to him being awarded the Nobel Prize in Medicine in 1998, in 
conjunction with Robert F. Furchgott and Ferid Murad for their work with NO. Research 
interests took off after NO was named “Molecule of the Year” in 1992. 
 
Figure 1.2.2a: Nitric oxide Lewis dot diagram 
 NO is produced in the body principally through nitric oxide synthases (NOSs).5-6 
In general, NOSs are responsible for the NO produced in eukaryotic cells; they are found 
in animals, partly conserved in bacteria and in some algae.7 Other organisms, including 
land plants, use alternative methods like nitrite reduction.7  
Basal levels of NO are produced by the constitutive isoforms (cNOS) of nitric oxide 
synthase, which continuously produces NO in the picomolar to nanomolar levels necessary 
for signaling. There are two isoforms of cNOS, one originally discovered in vascular 
endothelial cells (eNOS) and a neuronal isoform found in the brain (nNOS), they have 
since been discovered in other tissues.8-9 Its role as the EDRF, responsible for the dilation 
of blood vessels, is one of its basal functions in vascular endothelial cells. NO activates 
soluble guanylate cyclase (sGC), an enzyme involved in vasodilation.10 In the central 
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nervous system, NO mediates the increase of cyclic guanosine monophosphate (cGMP) 
via the activation of glutamate receptors.11-13 The activation of cGMP controls vascular 
tone, participates in the control of blood pressure, and regulates the distribution of flow 
between vascular beds, including the brain and skeletal muscles.10 
Beyond cNOS, NO can also be produced in larger quantities (micromolar) by the 
inducible isoforms of nitric oxide synthase (iNOS), in response to stimuli such as 
endotoxins and cytokines, which are often released in response to infections, inflammation, 
and other pathologies.10, 14-15 iNOS is calcium-independent and was discovered in 
macrophages, with roles in the immune system; with responses to burn injuries, arthritis, 
and inflammatory bowel diseases (IBSs).15 At the micromolar levels produced by iNOS, 
NO can display toxic effects that work to aid the immune system by killing 
microorganisms, viruses, and parasites.10 
1.2.3 Downstream NO Signaling & Matrix Metalloproteinase’s (MMP). 
 NO plays several roles in wound healing. It has a central role in physiological and 
pathological processes of angiogenesis where it can promote collagen deposition at the 
wound site, which helps to increase the strength of the healed wound.16-18 Inhibition of NO 
at a wound site results in a decrease of collagen produced and decreased formation of 
granulation tissue.19 In the vasculature, NO can stimulate cell proliferation, provide 
protection from apoptosis, prevent against thrombosis, and is the mediator for the vascular 
endothelial growth factor (VEGF).17 In addition, NO has been shown to display some 
antiplatelet, antiatherosclerotic, haemodynamic and neuroprotective properties.10 
Topically applied NO has been shown to increase dermal microcirculation in skin models.20 
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 Downstream signaling effects of NO are observed throughout cell physiology. For 
example, NO activates guanylyl cyclase which can then produce cyclic guanosine 
monophosphate (cGMP). One of cGMP’s signaling roles include the dilation of blood 
vessels. Other effects of NO include the influence of other proteins, such as matrix 
metalloproteinase’s (MMP). MMP’s play a central proteolytic role in extracellular matrix 
remodeling, during processes such as cell proliferation, angiogenesis and more.21 A NO 
regulatory effect on the activity of MMPs has been observed. In a wound model by Ridnour 
et al. media exhibiting peak MMP activity increased corresponded to a vascular cell 
migration that was MMP-9-dependent, which suggested that MMP-9 is a key physiologic 
mediator of the effects of NO.22 Multiple pathways of MMP activation by NO have been 
discovered: MMP’s are influenced by cGMP (a reaction product of NO), VEGF-stimulated 
cerebral MMP has been found to be mediated through NO produced by iNOS, elevated 
levels of NO has been found to correspond with MMP activity in diseases like rheumatoid 
arthritis, where cartilage breakdown is predominant, or cancer, where rapid remodeling and 
angiogenesis takes place.22-24 
1.2.4 Medical Effects of NO 
 Certain disease states and health complications can deteriorate by the body’s 
inefficient production of NO, or its decrease in sensitivity to NO. NO activity can be 
tracked by the levels of the post translational modification S-nitrosylation (SNO), which is 
the result of NO signaling. This NO adduct on cysteine thiols (SNOs) can be investigated. 
Abnormal S-nitrosylation can be found in various human diseases. Such is the case for 
diabetes, where impaired function of NO synthase is prevalent. Diabetic peripheral 
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neuropathy is a long term complication for diabetic patients and can lead to amputation; 
this is theorized to be caused by lack of NO.25-26 It was found that diabetic patients 
displayed an increase in red blood cell SNO-hemoglobin that displayed a defective release 
of the NO adduct.27 Increased SNOs in the joints can be found with arthritis due to local 
NO production, there is an increase in airway SNOs during pneumonia due to the induction 
of iNOS, and the S-nitrosylation of MMP-9 can be found during stroke via the activation 
of nNOS.27 A decreased amount of SNO-hemoglobin in red blood cells can be found in 
pulmonary hypertension due to low oxygen saturation and a deacrease in SNO-proteins in 
the lung can be found with pre-term birth due to decreased NOS expression.27 
NO is already incorporated into various treatment plans for many cardiopulmonary 
disorders, including for sickle cell disease, lung and heart transplants, and for newborns 
with pulmonary hypertension.28 It has been used for biomedical devices, such as stents. A 
stent with NO donor-containing liposomes has been shown to enhance endothelial cell 
proliferation, while inhibiting smooth muscle cell proliferation for the purpose of fighting 
against thrombosis and restenosis.29-30 NO can also be used to disperse biofilms from 
accumulating on surfaces like catheters, implants, and on wounds.31 
 Due to NO’s role in wound repair, we have developed a novel NO generation 
system based on copper-chitosan complexes that can potentially be used for the topical 
generation of NO. Chitosan (derived from chitin) is a hydrophilic polysaccharide, made 
from D-glucosamine and N-acetyl-D-glucosamine monomers bound through ß(1→4) 
linkages.32 Chitosan is a biocompatible, biodegradable, non-toxic, and antimicrobial 
polymer.33 As well, it is already used for various medical purposes such as wound 
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dressings, tissue engineering, plastic surgery, and for drug delivery systems.33 Here, 
chitosan was chosen as the base matrix for the NO generation system due to its ability to 
chelate various metal ions, including copper (Figure 1.2.4a). A study by Martinez et al. 
showed that their nitric oxide releasing nanoparticles, a hydrogel/glass composite made 
using chitosan, had beneficial effects on wound closure using mouse models.16 The 
nanoparticles in this study used the glass properties of the composite to reduce nitrite to 
NO. The NO produced was tested as a therapeutic strategy against superficial skin 
infections; successful with both MRSA and MRSS bacterial strains.16 
 
 
Figure 1.2.4a: Postulated structure for Chitosan-copper complex. 
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1.2.5 Chitosan & Our Technology 
 Chitosan has previously been used in wound healing applications, mainly due to its 
antimicrobial properties and its ability to perform as a stand-alone film, while being 
supported by a backbone matrix (scaffolds), or as a gel. For instance, some success has 
been found with a chitosan-based, film-forming gel containing an antibiotic in diabetic 
mice wounds.34 Films, both made with chitosan alone and one with chitosan combined with 
silver oxide nanoparticles were used in rat models. Both of these films outcompeted the 
control group in a wound healing model, with a significant increase observed with the 
modified chitosan.35 These results were especially apparent in the early phases of wound 
healing. As well, chitosan-based scaffolds have shown an ability to enhance the process of 
tissue regeneration when combined with immobilized growth factors.36 Chitosan is a highly 
versatile biopolymer.  
 In this study, we present copper chitosan derivatives that produce NO by reducing 
nitrite. During this process copper is oxidized to the +2 state.37 Glucose, a reducing sugar, 
is added to the system to return copper to its +1 state.38-39 The overall process is 
schematically shown in Figure 1.2.5a (i), with the postulated mechanism of NO conversion 
is shown in Figure 1.2.5a (ii). Here, we made copper chitosan milli- and micro- sized 
particles and demonstrated the NO production using a NO analyzer, a cell culture model 
of wound healing, and by monitoring the intracellular NO target MMP-2 and -9. 
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(i) 
 
(ii) 
 
 
Figure 1.2.5a: Structures of Copper-Chitosan.  
(i) Copper-chitosan’s pathway to making nitric oxide. Nitric oxide reduced from 
nitrite via the oxidation copper (I) chitosan particles. The catalytic cycle is 
completed by cupper being reduced by the oxidation of glucose to gluconic acid.  
(ii) Postulated mechanism for NO production from nitrite and Cu+1. Nitrite (NO2-) 
binds to Cu(I), where it becomes protonated. Water is released to produce a copper-
nitrosyl (Cu(I)-NO+). Cu(I)-NO+ is then reduced by the copper center and nitric 
oxide is released. Cu(II) is reduced to Cu(I) to complete the catalytic cycle.  
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1.3 Methods 
 Chitosan and copper-chitosan particles were successfully produced on the micro- 
and milli-size scale. Milli-size particles were used for experiments, including experiments 
utilizing a Nitric Oxide Analyser to test for NO production, scratch assays to test for 
cellular response in regards to cell growth, as well as a matrix metalloproteinase (MMP) 
activity assays for a closer look at the NO effect at a cellular level. Chitosan and copper-
chitosan particles milli-particles will be respectively referred to as “chito” and “Cu-chito” 
henceforth.  
1.3.1 Copper-Chitosan Micro-Particle Preparation 
Soft lithography and molding techniques were used to prepare 
polydimethylsiloxane (PDMS) microfluidics apparatus, containing micro channels used to 
control fluid flow. The apparatus is shown in Figure 1.3.1a (i). The design was adapted 
from Sugaya et al.’s apparatus for micrometer-sized chitosan hydrogel beads.40  
The PDMS mold was designed to have the dimensions of a glass microscope slide, 
25.4 x 76.2 mm. To complete assembly, the mold was clamped between two microscope 
slides using small binder clips. Tubing connected each channel to a syringe, via a 20G 
needle connection. This full set up is shown in Figure 1.3.1a (ii). 
The mold contained four micro channels placed in a cross formation, three for 
reagents and one to act as an exit channel. Particles are formed by taking advantage of the 
solubility properties of chitosan. Acid-dissolved chitosan solutions were made by 
dissolving 0.05% (w/v) chitosan in 0.1 M acetic acid. This dilute chitosan solution was 
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pumped down the vertical micro channel at a speed of 5 µL/min from a 10 mL syringe, 
using a NE-300 Syringe Pump. This continuous flow was disrupted by 50 mM NaOH being 
pumped by two other syringe pumps delivering NaOH solutions from 60 mL syringes into 
their respective horizontal micro channel at a rate of 50 µL/min. Due to chitosan being 
insoluble in basic pH levels, particles are essentially ‘pinched’ off from the original flow. 
This forms reproducible particles under 5 microns in size. Copper chitosan micro-particles 
were produced using the same protocol, but with copper chloride mixed with the chitosan. 
 A sample of micro-particles were reacted with 5-(dimethylamino)naphthalene-1-
sulfonyl chloride (dansyl chloride, DNSC) to produce fluorescent particles. To do this, a 3 
mL solution of concentrated micro-particles made and suspended in 50 mM NaOH was 
mixed with 1.5 mg of dansyl chloride and left at room temperature for 2 hours. The particles 
were then spun down using a centrifuge on the lowest setting for two minutes, to form a 
loose pellet. The supernatant containing excess dansyl was removed and the particles were 
resuspended with 50 mM NaOH. This process was repeated and the particles were mounted 
on microscope slide and sealed with a coverslip. A Zeiss Axiovert 200 microscope, 
outfitted with a QImaging Retiga EX digital camera and a filter cube to accommodate 
dansyl fluorescence (excitation filter, 350 nm, and emission filter, 500 nm-600 nm), was 
used to obtain a fluorescent image.  
The nucleophilic attack of dansyl chloride by the amine group of chitosan can be 
seen in Figure 1.3.1b. The basic conditions can ensure the deprotonation of chitosan’s 1° 
amine and aid with deprotonation of the dansyl-chitosan 2° amine.  
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(i) 
 
(ii) 
 
Figure 1.3.1a: Particle-producing apparatus.  
(i) PDMS microfluidics apparatus for chitosan micro-particle production. Three 
reagent channels converge where the particles are formed and the resulting particle 
suspension exits out of the exit channel. 
(ii) Assembled microfluidics apparatus. The PDMS apparatus is clamped between two 
glass slides. NaOH and a dilute chitosan solution is pumped into the apparatus via 
syringe pumps and the resulting solution is collected. 
  
Chitosan 
NaOH                NaOH 
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Figure 1.3.1b: Amine group of chitosan reacting with dansyl chloride. 2 hours RT, basic 
conditions. 
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1.3.2 Copper-Chitosan Milli-Particle Preparation 
To produce copper chitosan milli-particles (Cu-chito), 2% (w/v) chitosan was 
allowed to mix with an excess of copper chloride (CuCl2). The resulting Cu-chitosan 
complex was dissolved with the addition glacial acetic acid to obtain a concentration of 1% 
(v/v) acid. Excess Cu precipitate was allowed to separate from solution overnight and was 
discarded. This wait period also allowed for any incorporated air bubbles to be removed. 
Plain chitosan milli-particles (chito) were produced in an identical way but without adding 
CuCl2, while the solution did not require removing precipitate, excessive air incorporated 
adds difficulty while producing the particles. Thus, minimal mixing was used or the 
solution was prepped and left to rest overnight. 
The resulting viscous solution was dispensed via a 27G needle and a 10 mL syringe. 
A NE-300 Syringe Pump dispensed the solution so drops fell in a dropwise manner into a 
1 M NaOH solution. The resulting spherical particles, Cu-chito or chito, were thoroughly 
rinsed with distilled water to remove excess base and left overnight in phosphate buffer 
(pH 7.4, 0. 1M). This is to reduce particle pH closer to neutral. The particles were rinsed 
again and dehydrated at room temperature. A count of 10 Cu-chito particles weighed in at 
3.0 ± 0.03 mg with individual particles being <1 mm in diameter. 
1.3.3 Nitric Oxide Detection 
Authentic NO was detected using a Sievers NO analyzer (NOA, model 280i, GE 
Analytical Instruments, Boulder, CO, USA). The NOA 280i was set up using the standard 
NO2
- measurement mode and standardized with NO2
- according to manufacturer protocol.  
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Chitosan milli-particles were added to an excess amount of dithiothreitol (DTT) 
until the colour changed from dark purple to a pale yellow. This was done to reduce Cu(II) 
to Cu(I), allowing Cu to be in an active state. The particles were washed with 100mL of 
PBS to remove the excess DTT. 
Chitosan (chito) or copper-chitosan (Cu-chito) particles of ~0.50 g, were placed in 
22 mL screw cap vials, and were degassed under nitrogen for 5 minutes. 2 mL of 100 µM 
sodium nitrite (NaNO2) ± 1 mM glucose was added. After allotted 15, 30, 45 or 60 minutes 
of reaction time had passed, 1.5 mL of headspace gas was removed with a 2.5 mL syringe 
(Hamilton 1000 Series Gastight Syringe) and injected into the NOA reaction vessel. The 
NOA reaction vessel was set up as per manufacturer’s protocol. Control samples omitted 
chitosan particles. Results were obtained via NOA peak area and compared to a standard 
curve created by adding nitrite into I-3 (50 mg) in acetic acid (17.4M) described by Piknova 
et al.41 All experiments were conducted in triplicate.  
1.3.4 Cell Studies 
Human retinal pigmented epithelium, ARPE-19 (ATCC® CRL- 2302TM) cells 
were purchased from ATCC (Manassas, VA, USA) and grown in Dulbecco's Modified 
Eagle Medium, Nutrient Mixture F-12 (DMEM/F12) supplemented with 10% fetal bovine 
serum (FBS) and 1% penicilium/streptomycin antibiotic solution, incubated at 37 °C with 
5% CO2. 
ARPE-19 cells were used for scratch assays. They were plated in 6-well cell culture 
plates and grown to approximately 90% confluence. Using a rubber ended cell scraper, 
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cells were removed to form a linear artificial wound. Data was organized by wound size. 
With the field of view taken into consideration, the average wound size was 1.8 mm2, with 
the smallest being 0.8 mm2 and the highest being 4 mm2. 
The milli-particle-bound Cu2+ was reduced with DTT, washed, and placed in 
sterilized polydimethylsiloxane (PDMS) cups with 40 µL of nitrite (100 µM NO2
–) ± 
glucose (0.1 or 1.0 mM). The PDMS cups were produced following previous methodology 
of our group, as described in Faccenda et al.42 The cups adhered to plate cover, and were 
suspended in the medium with ~2 mm clearance from well bottom. They were placed in 
the well approximately ~1 cm away from the center of the artificial wound (Figure 1.3.4a 
(i, ii)). NO as well as other gases like O2, H2S etc. freely diffuse through the PDMS, while 
salts and hydrophilic compounds like the nitrite and glucose do not.42 Control samples refer 
to PDMS cup containing nitrite solution only.  
A Zeiss Axiovert 200 microscope, outfitted with a QImaging Retiga EX digital 
camera, was used to take DIC cell images. The number of cells in the scratch wound area 
at 0 and 48 hours were compared and the net number of new cells was reported (Equation 
1.3.4a). Images were obtained at 0 and 48 hours and the cell counts were calculated using 
Image-J software. 
Equation 1.3.4a: 𝑵𝒆𝒕 𝒄𝒆𝒍𝒍 𝒈𝒓𝒐𝒘𝒕𝒉 =  𝑪𝒆𝒍𝒍 𝒄𝒐𝒖𝒏𝒕𝟒𝟖 𝒉𝒓𝒔 − 𝑪𝒆𝒍𝒍 𝒄𝒐𝒖𝒏𝒕𝟎 𝒉𝒓𝒔 
  
  
20 
 
 
(i) 
 
(ii) 
 
 
Figure 1.3.4a: Scratch assays with ARPE-19 mammalian cell culture.  
(i) Particles with nitrite ± glucose confined by PDMS cups, adhered to plate cover, 
were suspended in the medium with ~2 mm clearance from well bottom.  
(ii) An illustration of the relative position of the PDMS cups with respect to the 
artificial wound, which spanned the vertical length of each well. 
  
PDMS cup containing:  
Particles + Nitrite ± Glucose 
Artificial Wound 
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1.3.5 Matrix Metalloproteinase (MMP) Activity 
Gelatin zymography was utilized to identify matrix metalloproteinase-2 (MMP-2, 
gelatinase A) and -9 (MMP-9, gelatinase B). This technique can be used to identify the 
type of gelatinase, relative amount, and activation status (latent vs active).43 Zymography 
works by impregnating the resolving layer of SDS-PAGE gels with the peptide substrate 
of the enzyme of interest. Protein in non-reducing conditions is electrophoresed. The gel is 
then incubated with the cofactors necessary for reaction to occur. Gelatinase activity is 
localized where the protein is present and white bands can be viewed upon distaining, in 
the areas where the gelatin was hydrolysed.  
A standard gelatin zymography protocol (Abcam) was followed.44 ARPE-19 cells 
were grown in 10 cm plates to 60% confluence. Using the width of a rubber ended cell 
scraper (1.7 cm), a vertical wound was made down the length of the plate. Removed cells 
and media was washed off with sterile PBS then grown with DMEM/F12 media lacking 
FBS. Cells were treated with 3 PDMS cups filled with their respective treatments, cups 
with 40 µL of nitrite (100 µM) ± glucose (1.0 mM) ± particles. After 48 hours, cell media 
was collected and analyzed via protocol. In overview: samples are run using non-reducing 
sample buffers on an SDS-PAGE gel co-polymerized with gelatin, SDS is washed out of 
the gel and it is incubated for 24 hours with the cofactors necessary to allow for gelatinase 
activity. The gel is then stained and destained, areas where the gel becomes clear is where 
the gelatin was hydrolysed by the enzymes. The bands appear as clear bands on blue 
background.  
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The resulting band area of each sample was processed through Image-J software. 
Values reported were normalized to the control data.  
1.3.6 Statistical Analysis 
Data was expressed as mean ± standard deviation. Two-tailed t-tests determined 
statistically significant differences at a 95% confidence interval. Statistical significance is 
determined by t being greater than the critical value (t > c.v.). 
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1.4 Results  
1.4.1 Copper-Chitosan 
The microfluidics apparatus was successfully used to make particles <10 microns 
in size with an apparent average of around 3 μm. The particles themselves are spherical 
and can be produced with and without copper. Shown in Figure 1.4.1a (i) is an image of 
copper-chitosan micro-particles made fluorescent by dansyl chloride. The particles are not 
considered robust, attempts to neutralize the pH result in dissolved particles and when left 
in their original basic media they aggregate relatively quickly. They are easy to produce 
when following protocol, however obtaining a large number of concentrated particles can 
take several days depending on the quantity desired. Immediate, unconcentrated particle 
solutions is suitable for imaging. Changing variables can change particle shape. For 
example, increasing the concentrations of chitosan produced varying shapes, such as longer 
cylindrical fibers (not shown). 
The milli-particles, chito and Cu-chito, were used in experiments for NO detection, 
as well as for cell studies. The particles can maintain their integrity over several rounds of 
reduction with DTT and handling, thus they are considered relatively robust. In Figure 
1.4.1a (ii), there is visible swelling while the particles are hydrated, however upon 
dehydration they return to their original size. This swelling does not compare to the fully 
hydrated particles prior to being de-hydrated. These particles can be seen in Figure 1.4.1a 
(iii-iv). After particles are reduced with DTT and washed, they can be left in a N2-purged 
vial for several days before visible oxidation (green to blue colour change) is seen. In 
comparison, particles exposed to air will re-oxidize overnight. The shelf life of reduced 
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particles could be increased by storing them in an inert atmosphere. Particles used for 
experiments were utilized immediately after the reduction and subsequent washes.  
 While milli-sized particles were successfully formed and utilized, copper-chitosan 
can be manipulated in a variety of ways to increase functionalization and application 
potential. Copper-chitosan micro-particles were produced using microfluidic techniques 
and the milli-particles can be ground into a fine powder. This could allow for incorporation 
into gels, creams, eye drops, wound washes, or other forms of topical application. Copper-
chitosan can also be made into a film (not shown), for incorporation onto biomedical 
devices or wound dressings. As well, it can be fixed onto gauze (shown), for uses as a 
wound dressing; preliminary gauze NOA 280i experiments showed that copper gauze is 
capable of NO release (not shown). Figure 1.4.1a (v) shows some of these forms of 
chitosan, including milli-particles, chitosan powder, and copper-chitosan fixed onto gauze.  
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(i) 
 
(ii) 
 
(iii) 
 
(iv) 
 
 
Figure 1.4.1a (i-iv): Various forms of chitosan and copper chitosan.  
(i) Fluorescent microscope image of copper-chitosan micro-particles, taken after a 
reaction with dansyl chloride. 
(ii) Left: copper-chitosan milli-particles. Right: copper-chitosan milli-particles after 
Cu2+ was reduced to Cu1+ by 0.5 M DTT in H2O; the particle size increases 
significantly due to hydration during the reduction process. 
(iii)Freshly prepared chitosan (chito) milli-particles, fully hydrated and not yet dried 
for use. Shown in 100 mL beaker. 
(iv) Freshly prepared copper-chitosan (Cu-chito) milli-particles, fully hydrated and not 
yet dried for use. Shown in 100 mL beaker. 
 
10 microns 
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(v) 
 
 
Figure 1.4.1a (v): Various forms of chitosan and copper chitosan.  
(v) (A1) Chitosan milli-particles 
(A2) Chitosan powder 
(A3) Untouched gauze 
(B1) Copper-chitosan milli-particles 
(B2) Copper-chitosan milli-particles ground into a powder 
(B3) Copper-chitosan fixed onto gauze. 
  
(A1)           (A2)       (A3) 
 
 
(B1)           (B2)       (B3) 
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1.4.2 Nitric Oxide Detection 
The Sievers NOA 280i was used to demonstrate that the Cu-Chito milli-particles ± 
glucose can produce authentic NO. In these experiments, the milli-particles + nitrite ± 
glucose were placed in degassed gas-tight vials, three vials at each time point, and each 
vial was only sampled once at 15 minute intervals up to 60 min. The graphical results at 
the various time points can be seen in Figure 1.4.2a (i). Peak data was converted to nmol 
amounts of NO per gram of milli-particles and adjusted for the total headspace of each 
reaction vial. Each sample, including the control samples, contained 100 µM NO2
– ± 10 
mM glucose. In Figure 1.4.2a (ii) the data is represented as the rate of NO produced/min. 
As indicated in Figure 1.4.2a, the milli-particles did produce NO. The level of NO detected 
by Cu-chito treatments in the presence of glucose did not result in statistically significant 
differences in comparison to the Cu-chito treatments without glucose present. 
The NO production rate plot (Figure 1.4.2a (ii)) was more revealing of the reaction 
dynamics. The maximum rate of NO production was ~ 1.40 nmol/min (Cu-chito) and 1.08 
nmol/min (Cu-chito + glucose). Beyond this point the NO production rate steadily 
decreased to ~0.24 nmol/min (Cu-chito) and ~0.27 nmol/min (Cu-chito + glucose). 
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(i) 
 
(ii) 
 
Figure 1.4.2a: NO signal detected by chitosan milli-particles as observed by the 
Sievers NOA 280i. Active particles were left to react with 100µM nitrite ± 1.0mM glucose, 
with gas samples were taken every 15 minutes from separate vials i.e. each vial at each 
time point was sampled only once.  
(i) Values represent nmoles of NO produced in the total headspace (20 ml) of reach 
reaction vial, adjusted for particle mass. 
(ii) The data expressed as rate of NO produced by Cu-chito and Cu-chito + glucose 
over sampling time.  
0
5
10
15
20
25
30
15 Minutes (n=3) 30 Minutes (n=3) 45 Minutes (n=3) 60 Minutes (n=3)
D
e
te
ct
e
d
 N
O
 (
n
m
o
l/
gr
am
)
Particle Reaction Time
Glucose Control Nitrite Control Chito + Glucose Chito Cu-Chito + Glucose Cu-Chito
0
0.5
1
1.5
2
0 10 20 30 40 50 60 70
R
at
e
 o
f 
N
O
 P
ro
d
u
ct
io
n
 
(n
m
n
o
l/
m
in
/g
ra
m
)
Time (min)
Cu-Chito + Glucose
Cu-Chito
  
29 
 
 
1.4.3 Cell Studies 
Scratch assays were performed in order to simulate an in vitro wound model, in 
order to test our novel NO releasing particles. They can provide insight into cell–matrix 
and cell–cell interactions, cell migration, cell proliferation, and can mimic cell migration 
during wound healing. The data collected here provides the net number of new cells in the 
wound area, with the data collected at 0 hours and 48 hours. The various cell treatments, 
of nitrite ± Cu-chito or chito, and ± glucose, were prepared into a PDMS cup and placed 
with the cell for the duration of the 48 hours.  
The scratch assay experiments were conducted using ARPE-19 mammalian cell 
culture. The reagent controls (nitrite ± glucose) and the NO generation system (chito or 
Cu-chito with nitrite ± glucose) were isolated from the cells by placing them inside of 
PDMS cups (Figure 1.3.4a (i, ii)) which are impermeable to ionic and hydrophilic 
molecules but allow gases such as NO to pass through. Table 1.4.3a displays the number 
of new cells grown in the wound for each treatment type.  
Overall, the Cu-chito showed an increase in number of cells in the wound, with 
around ~200-300 new cells more than the controls. Using a 95% confidence interval, this 
is considered statistically significant. This result is very promising, especially since the 
chito particles without copper only showed around 0-40 new cells in comparison to the 
controls, which is statistically insignificant. To visualize the effect of the Cu-chito particles, 
Figure 1.4.3a compares 0 hours to 48 hours on the number of cells, for data with a wound 
size of 1.8 mm2. 
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 The data in Table 1.4.3a also reveals the difference between having glucose present 
or absent. With glucose, Cu-chito treatments showed an increase of 152% more cells in the 
wound in comparison to control groups, while Cu-chito treatments with nitrite alone 
showed 130% more cells in the wound. In comparison to each other, the Cu-chito with 
glucose treatments displayed a significant increase of ~118% more cell cells in the wound 
in comparison to treatment of Cu-chito and nitrite. However, Cu-chitosan with 0.1 mM 
glucose vs. 1 mM glucose were statistically insignificant in comparison to each other. This 
is not completely unexpected, since both their concentrations are large; this indicates that 
0.1 mM or less of glucose may be sufficient to elicit a similar response. 
 We also wanted to see if the effect of particle-generated NO would have a different 
effect depending on the size of the manually-obtained wound. To do this we created a 
distribution of pseudo-wounds wound areas ranging from 0.8 mm2 to 4.0 mm2. To further 
analyze the effect wound size had on the effectiveness of the Cu-chito treatments, the data 
was reorganized by the wound size and further analyzed with two-tailed t-tests for 
statistical significance. The control and Cu-chito data is reorganized by wound size in 
Figure 1.4.3b, with the corresponding statistical information shown in Table 1.4.3b. 
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Table 1.4.3a: Scratch assay results with ARPE-19 mammalian cell culture. Various 
treatment types of chitosan milli-particles and the net number of new cells after 48 hours. 
Statistical comparison is to the control data. Two tailed t-test: statistical significance is 
determined by t being greater than the critical value (t > c.v.). Number ‘n’ refers to number 
of data values used. 
Treatment Type: New Cell Count: 
95% Confidence 
Interval: 
Control (n=72) 588.6 ± 181.1  
Cu-Chito (n=54) 763.9 ± 231.3 
Significant 
(4.8 > 2.0) 
Cu-Chito + 0.1 mM Glucose (n=48) 898.0 ± 219.4 
Significant 
(8.3 > 2.0) 
Cu-Chito + 1.0 mM Glucose (n=54) 874.9 ± 173.7 
Significant 
(8.9 > 2.0) 
Chito (n=24) 621.7 ± 154.5 
Not Significant 
(0.8 < 2.0) 
Chito + 0.1 mM Glucose (n=24) 610.0 ± 257.0 
Not Significant 
(0.4 < 2.0) 
Chito + 1.0 mM Glucose (n=24) 583.1 ± 215.4 
Not Significant 
(-0.1 < 2.0) 
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(i) Nitrite Control  
  
(ii) Cu-Chito + Nitrite 
  
 
Figure 1.4.3a (i-ii): Representative scratch assay images for pseudo-wounds of 1.8 
mm2 in size. Reported as the difference in number of cells at 0 and 48 hours, as counted 
by ImageJ: 
(i) Nitrite Control sample- net number of new cells: 588.6 ± 181.1 cells 
(ii) Cu-Chito + Nitrite treatment- net number of new cells: 763.9 ± 231.3 cells 
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(iii) Cu-Chito + Nitrite + 0.1 mM Glucose 
  
(iv) Cu-Chito + Nitrite + 1.0 mM Glucose 
  
 
Figure 1.4.3a (iii-iv): Representative scratch assay images for pseudo-wounds of 1.8 
mm2 in size. Reported as the difference in number of cells at 0 and 48 hours, as counted 
by ImageJ: 
(iii)Cu-Chito + Nitrite + 0.1mM glucose treatment- net number of new cells: 898.0 ± 
219.4 cells  
(iv) Cu-Chito + Nitrite + 1.0mM glucose treatment- net number of new cells: 874.9 ± 
173.0 cells 
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Figure 1.4.3b: Cu-chito scratch assay results, organized by wound size. The Cu-chito 
(nitrite ± glucose) data sets are compared to the respective control (nitrite) data. The net 
number of cells in the wound at 48 hours is shown, with the data sets organized by 
increasing wound size analyzed. (Note: * indicates significance in comparison to the 
respective control data at a 95% confidence interval; NS = not significant. Statistics 
displayed in Table 1.4.3b)  
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Table 1.4.3b: Statistics for scratch assay results, with data organized by wound size. 
Various treatment types of chitosan milli-particles and the net number of new cells after 48 
hours. Statistical comparison is to the respective control data. Two tailed t-test: statistical 
significance is determined by t being greater than the critical value (t > c.v.). Number ‘n’ 
refers to number of data values used. 
Wound Size: Treatment Comparisons: 
95% Confidence 
Interval: 
0.80-1.39 mm2 
Control (n=21) 
  Cu-Chito (n=13) 
Not Significant  
 (0.4 < 2.0) 
 
Control (n=21) 
  Cu-Chito + 0.1 mM Glucose (n=10) 
Significant  
 (2.5 > 2.00) 
 
Control (n=21) 
  Cu-Chito + 1.0 mM Glucose (n=13) 
Significant  
 (3.1 > 2.0) 
1.40-1.59 mm2 
Control (n=13) 
  Cu-Chito (n=7) 
Significant  
 (2.8 > 2.1) 
 
Control (n=13) 
  Cu-Chito + 0.1 mM Glucose (n=7) 
Significant  
 (3.5 > 2.1) 
 
Control (n=13) 
  Cu-Chito + 1.0 mM Glucose (n=14) 
Significant  
 (4.0 > 2.0) 
1.60-1.90 mm2 
Control (n=12) 
  Cu-Chito (n=16) 
Significant  
 (3.2 > 2.0) 
 
Control (n=12) 
  Cu-Chito + 0.1 mM Glucose (n=10) 
Significant  
 (3.0 > 2.0) 
 
Control (n=12) 
  Cu-Chito + 1.0 mM Glucose (n=13) 
Significant  
 (4.9 > 2.0) 
2.00-2.39 mm2 
Control (n=11) 
  Cu-Chito (n=9) 
Significant  
 (3.7 > 2.1) 
 
Control (n=11) 
  Cu-Chito + 0.1 mM Glucose (n=8) 
Significant  
 (5.8 > 2.1) 
 
Control (n=11) 
  Cu-Chito + 1.0 mM Glucose (n=8) 
Significant  
 (5.3 > 2.1) 
2.40+ mm2 
Control (n=14) 
  Cu-Chito (n=11) 
Significant  
 (3.9 > 2.0) 
 
Control (n=14) 
  Cu-Chito + 0.1 mM Glucose (n=13) 
Significant  
 (5.3 > 2.0) 
 
Control (n=14) 
  Cu-Chito + 1.0 mM Glucose (n=6) 
Significant  
(5.0 > 2.1) 
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1.4.4 Gelatin Zymography for MMP Activity 
 Samples processed by gelatin zymography immediately after the 48 hour treatments 
can be seen in Figure 1.4.4a (i-ii). With the area of each band normalized to the nitrite 
control, the results show a 60% increase in MMP activity after Cu-chito and Cu-chito + 
glucose treatments. The 73 kDa band was used for this measurement due to the clear affect 
that the particle treatments displayed. With the nitrite control being set to 100 ± 13%, the 
water control compared at 99 ± 26%. Cu-chito displayed 164 ± 26% and Cu-chito with 
glucose added displayed 160 ± 5% of the nitrite control. The quantification of the band 
density is summarized in Figure 1.4.4a (iii).  
 Further differences between the control samples and the copper particle samples is 
the presence of more bands displaying gelatinase activity. The copper particle treatments 
appear to induce other gelatinase enzymes, with a somewhat defined band appearing at 86 
kDa. This band was not seen in comparison to control samples. The molecular weight 
(MW) of this band, along with the prominent 73 kDa band, was calculated using the 
molecular weight (MW) ladder, which appears on the left of each gel image. This was done 
using a log(MW) Vs Rf graph (not shown). 
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 (i) 
 
 (ii) 
 
 
Figure 1.4.4a (i-ii): MMP activity via gelatin zymography.  
(i) Zymography gels of copper-chitosan milli-particle treatments. Left to right, the gel 
lanes contain prestained protein ladder, followed by two Cu-chito with nitrite 
samples and one Cu-chito with nitrite and glucose sample, run in duplicate. 
(ii) Zymography gels of control treatments. Left to right, the gel lanes contain 
prestained protein ladder, followed by two nitrite control samples and one water 
control sample, run in duplicate. 
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(iii) 
 
Figure 1.4.4a (iii): MMP activity via gelatin zymography.  
(iii)Band densities of bands located at 73 kDa, calculated using ImageJ. Data is 
normalized to the nitrite control data. Samples were processed immediately after 
their respective 48 hour treatments. (Note: * indicates significance in comparison 
to nitrite control data at a 95% confidence interval; NS = not significant) 
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1.5 Discussion 
 This is a study into the production of a novel NO releasing particles at the milli and 
micro scale, using chitosan as a matrix for a copper catalyst. The milli-sized particles were 
tested for the authentic production of NO using the NOA 280i and underwent testing in an 
in vitro wound healing model. In addition to scratch assays, matrix metalloprotease 
enzymes were chosen as an extracellular target to observe the effect of the NO treatments. 
1.5.1 Nitric Oxide Detection 
 NO production was detected by taking readings of the headspace gas of sample-
containing vials. Copper containing particles successfully produced detectable NO gas 
over the course of an hour, while controls and particles lacking in a copper aspect produced 
comparatively minimal signals.  
Beyond this, there are a couple of interesting takeaways that the data provides. First, 
the presence of glucose had a statistically insignificant effect. Glucose neither helps nor 
hinders the NO production potential exhibited by the particles. This may be attributed to 
the short time scale that the reaction was monitored and overall does not disprove the theory 
that glucose could aid in catalytic turnover over time.  
As well, while the copper samples give consistent readings in the range of 15-20 
nmol/g, the rate of NO production over time decreases over the course of the hour. One 
reason for this could be the closed system that the readings were taken. In this closed 
system, NO could be reacting with Cu2+ and being converted back to nitrite; this has been 
demonstrated by Sarma & Mondal.45 Since NO(g)  (the detected species) is in equilibrium 
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with NO(aq) this leads to a suppressed value of the NO produced by the particles, in 
comparison to its maximum potential. This equilibrium is shown in Equation 1.5.1a. This 
situation is not expected to occur in the wound healing cell model used, as the NO(g) 
generated would diffuse away to induce cellular signaling. With NO(g) being removed from 
the equation, the reaction would be pushed towards the product side.  
 Equation 1.5.1a:  
1.5.2 Cell Studies 
Interesting patterns arose when comparing wound size. The graph (Figure 1.4.3b) 
shows how the two glucose treatments remain similar at every size point. The Cu-chito 
remains competitive with glucose treatments for sizes 1.4-1.9 mm2. If wound sizes 
remained in this range, the effect of glucose would remain inconclusive. At sizes 2 mm2 
and higher, with more room for cells to grow, glucose treatments show increased number 
of new cells in the wound suggesting that, as we postulated, sustained NO production can 
be maintained as long as there is sufficient glucose present to recycle the oxidized copper. 
Unfortunately, we could not demonstrate the sustained NO released from the particles with 
the closed discontinuous system for NOA detection of NO. It is possible to use the NOA 
280i for live NO readings and this has been done46, however would require building a gas 
tight chamber for the cells to incubate, with 5% CO2 incoming and all air being fed into 
the machine for NO detection. 
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 The effect of glucose is seen in this data. Cu-chito treatments that combined nitrite 
and glucose had a significant increase in new cells in the wound in comparison to 
treatments with nitrite alone. Cu-chito without the addition of glucose grew an average of 
170 more cells per experiment than the control experiments. Whereas Cu-chito with the 
presence of glucose grew an average of 300 more cells per experiment, compared to the 
nitrite control (data can be observed in Table 1.4.3a). This is determined as statistically 
significant, with a two tailed t-test comparing these values (data not shown). Thus, it 
supports our hypothesis that the addition of glucose aids in the production of NO.  
1.5.3 MMP as a NO Sensor 
The technique of gelatin zymography is used to identify the activity of MMP-2 and 
MMP-9, both of which have gelatinase activity. Due to the correlations between NO and 
MMP activity, this was chosen to observe the changes that the Cu-chito treatments can 
enact on an enzymatic level. Zymography gels can theoretically be used to identify the type 
of gelatinase, relative amount, and activation status (latent vs active).43 In order to 
accurately identify activation status, an internal standard is required. Options for this 
include conditioned medium from HT1080 human fibrosarcoma cells, which contains 
MMP-2 (72kDa) and MMP-9 (92kDa).43 If these cells undergo treatment, the media can 
also contain active MMP-2 (62 kDa), another option is using purified protein, if available. 
Active MMP-9 is 82 kDa. 
There are also intermediate inactive forms of MMP-2 (64 kDa) and MMP-9 (85 
kDa), and the possibility of low-weight active forms of MMP-2 (45 kDa) and MMP-9 (67 
kDa). Viewing all these forms is possible do the SDS in the gel and in the sample buffer 
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that works to unfold the protein in a way that exposes the active site and allows for 
activity.43 The intermediate inactive form is found when samples contain endogenous 
tissue inhibitors of metalloproteinases (TIMPs); this band would be difficult to isolate due 
to the small difference in size to the respective active species. Low-weight active forms 
become an issue when protein samples are purposefully treated to obtain the active forms 
and are overexposed to the treatment.43 Since our samples are not obtained from a tissue, 
nor are they purposely treated, bands in these locations are not expected to occur.  
The copper containing samples displayed a marked increase in the protein 
observed. The band that best observes this change was the one seen at 73 kDa, since this 
band also appeared in the control samples (Figure 1.4.4a (i)). This is likely inactive MMP-
2, based on size. Copper samples also displayed a distinctive peak at 86 kDa which could 
correspond to a form of MMP-9 (Figure 1.4.4a (i)). To truly confirm the identity of the 
present enzyme, the use of an internal standard may be necessary. Otherwise techniques 
such as immunoblotting could be used. In terms of true quantification, ELISA assays would 
be the gold standard. To determine if expression levels is the cause of increase in MMP 
activities, reverse transcription polymerase chain reaction (RT-PCR) would have to be 
utilized.47-48 
The mechanism of change that NO effects in MMP’s can vary by MMP type or on 
the cell or tissue type in question. Studies suggest that NO effects activation of MMP’s 
through S-nitrosylation.49 Some research on human cells include rheumatoid synovial cells, 
where NO has be found to increase the expression levels of MMP-2.50 It was found that 
MMP-2 is regulated by NO in fibrosarcoma epithelial cancer cells.51 MMP-9 in human 
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placental tissue is activated by NO; with patients with gestational and pre-existing diabetes 
mellitus having reduced activity of the enzyme, due to the reduction of NO.52 NO effects 
MMP-9 in airway epithelial cells through an expression and activation; the use of NO 
donors in this study was found to promote wound repair through these methods.53 
While its is entirely possible that the ARPE-19 cells are reacting to the NO 
stimulation through an increase in MMP expression, the experimental work done cannot 
confirm this mechanism of action. With the evident increase in activity, S-nitrosylation 
activation is the simplest explanation. 
In regards to this project itself, the fact that these changes are observed at the 48-
hour mark indicate that the nitric oxide supplement via copper chitosan particles is 
providing long-lasting effects.  
  
  
44 
 
 
1.6 Conclusion  
  By complexing copper with chitosan polymer, nitric oxide releasing derivatives 
have been developed. Copper-chitosan micro- and milli- particles were produced using 
microfluidic techniques. Authentic nitric oxide production from copper-chitosan milli-
particles was observed using the Seivers Nitric Oxide Analyzer 280i. In vitro scratch assays 
with the ARPE-19 cell line resulted in an increase of cell new cells in the wound after 
treatment with the copper-chitosan milli-particles, as well as an even higher increase in cell 
new cells by supplementing glucose in the particle treatment. Using the activity of MMP 
proteins as a NO sensor resulted in Cu-chito treatments showing a 60% increase in cellular 
enzymatic activity in comparison to controls; the influence of NO can be observed at least 
up to the end of the 48-hour treatment.  
 There are many applications for the technology presented here. The size of the nitric 
oxide releasing micro-particles would allow for use in gels, creams, eye drops, wound 
washes, or other topical applications for a wound. Copper chitosan could be incorporated 
directly onto biomedical devices, or a wound dressing, gauze or otherwise. Our technology 
utilizes a minimal number of easily accessible, low-cost, components, as well as a 
minimally complex system for forming particles that can easily be adapted to an industrial 
setting. This puts our technology at a clear advantage in comparison to other NO releasing 
systems, for example, those that use NO donor compounds or other drugs that have to be 
independently synthesized.  
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1.7 Future Directions  
 Future work that could benefit this project includes battling the logistics of taking 
live readings of NO output over a greater period of time. Being able to assess the quantity 
of NO that the mammalian cells are utilizing versus how much is being outputted total 
would benefit in assessing the concentration of NO that would benefit the cells without 
releasing a concentration that becomes needlessly toxic. In addition, monitoring other 
extracellular effects would add useful insights to the effects of the treatments. The 
complications with this include the ability to measure endogenous proteins. Past work in 
this regard includes Western blot assays utilizing antibodies (Santa Cruz Biotechnology) 
that target fibroblast growth factor 2 (FGF-2) and vascular endothelial growth factor 
(VEGF), to no success in identifying the proteins at endogenous levels. Optimizing these 
experiments or pursuing different routes, including routes that take a closer look at MMP 
levels, is a possible future direction. Performing a Western blot while probing for S-
nitrosocysteine residues may be of interest.   
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CHAPTER 2: Study into an Allosteric Site of 
S-nitrosoglutathione Reductase (GSNOR) 
  
\\\\\\ \ 
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2.1 Chapter Summary  
S-nitrosoglutathione (GSNO), an endogenous S-nitrosothiol (SNO), plays a 
prominent role in nitric oxide (NO) signaling and bioavailability. S-nitrosoglutathione 
reductase (GSNOR) is the enzyme responsible for its metabolism. Due to this, GSNOR’s 
activity has a strong influence on SNO-protein levels. As such, furthering the 
understanding of GSNOR’s regulatory mechanisms is of great interest. Our group has 
noted a sigmoidal deviation in GSNOR’s steady state kinetics, in regards to GSNO 
concentrations. Our kinetic analysis yields a sigmoidal curve with a Hill coefficient (n) of 
1.49 ± 0.037; indicating positive allostery. Molecular docking (MD) simulations were 
performed and implicated the amino acid residues Gly321, Lys323, Asn185, and Lys188 
in the binding of an allosteric GSNO; in a location adjacent to GSNOR’s structural zinc 
atom. To further these studies, time-resolved electrospray (TRESI) microfluidics set up 
was utilized to perform hydrogen / deuterium exchange (HDX) mass spectrometry (MS) 
experiments. With a two second HDX reaction time, the peptides containing the residues 
Gly321, Lys323, and Lys188 displayed a decrease in deuterium uptake of 1.4%, 1.4%, and 
0.4%, respectively. These changes were calculated as the difference in deuterium uptake 
after the inclusion of GSNO in the GSNOR protein solution. This offers insight into the 
interactions of GSNO at these amino acid residues and ultimately supports the location of 
the allosteric site proposed by the MD studies.  
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2.2 Introduction 
2.2.1 GSNOR as ADH5 
S-nitrosoglutathione reductase (GSNOR) is an alcohol dehydrogenase class-3 
(AHD-3) enzyme encoded by the ADH5 gene, located on the reverse strand of 
chromosome 4 (4q23 – chr4:99993567 – 10000985).54 Sometimes referred to as ADH5, 
GSNOR has several other aliases and functions beyond its role in metabolizing the 
substrate S-nitrosoglutathione (GSNO).55 
Another main role of GSNOR is to act as a glutathione-dependent formaldehyde 
dehydrogenase (GSH-FDH, FALDH).56 ADH5 is critical in the metabolic elimination of 
formaldehyde. Formaldehyde can react with glutathione to form S-
(hydroxymethyl)glutathione (HMGSH) and from there ADH5 can oxidise it to S-
formylglutathione, this process is shown in Figure 2.2.1a. S-formylglutathione can then 
go on to undergo hydrolysis via S-formylglutathione hydrolase to produce formic acid and 
to regenerate GSH.57 ADH5 requires the cofactor NAD+ for this function and results in the 
formation of NADH, the cofactor required for GSNO reduction.  
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Figure 2.2.1a: ADH5 and its role in formaldehyde detoxification. GSH reacts with 
formaldehyde to produce HMG. ADH5 can then oxidise HMGSH to form S-
formylglutathione. S-formylglutathione is then hydrolyzed via S-formylglutathione 
hydrolase to reobtain GSH (not shown). 
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Other synonyms for GSNOR include chi polypeptide, and AHDX, FDH, and HEL-
S-60p. Despite being an alcohol dehydrogenase, ADH5 has a low affinity for ethanol, 
preferring instead to perform the oxidation of long-chain primary alcohols (with a 
preference with a double bond located in the β position), complex alcohols of high 
molecular weight, and omega-hydroxy fatty acids.58 
GSNOR is found in both prokaryotic and eukaryotic organisms, and highly 
conserved across most vertebrate species.59 GSNOR plays an important role in plants, the 
enzyme is necessary for normal growth and development.60 Arabidopsis thaliana plants 
occupies much of the plant GSNOR research available, however there has also been work 
involving peas (Pisum sativum L.), pepper (Capsicum annuum L.), sunflower (Helianthus 
annuus L.), the fungus Plasmopara halstedii, as well as maize and rice.60 GSNO’s role in 
S-nitrosothiol formation, the formation of reactive nitrogen species (RNS), and its ability 
to influence NO homeostasis, plants are at a severe disadvantage if they display atypical 
GSNOR activity or expression. 
In human tissue, ADH5 displays ubiquitous expression. Notably, GSNOR is found 
in the endometrium (RPKM 69.1), kidney (RPKM 68.7), fat (RPKM 61.5), liver (RPKM 
57.4), prostate (RPKM 62.0), ovary (RPKM 49.2), and esophagus (RPKM 53.3).61 
GSNOR is a cysteine rich homodimer, found in the nucleus and cytoplasm.62 It is a 
metalloprotein, containing two zinc atoms per monomer, while both are in the catalytic 
domain, only one is involved in catalysis while the other is considered a structural zinc. 
The molecular weight of a monomer is 39,724 kDa consisting of 374 amino acids 
(UniProtKB identifier: P11766) translated from 9 exons.58 The amino acids involved with 
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binding are highly conserved, especially Glu68 and Arg379 since they are important to the 
catalytic mechanism.58, 63 Cys45, His67, Glu68, and Cys174 are involved in the binding of 
the catalytic zinc atom while Cys97, Cys100, Cys103, and Cys111 bind the structural 
zinc.64 Amino acids Ala302-Gln307 are involved in the diner interface interactions.65 It is 
the amino acids of the interacting interface, and in the coenzyme binding domain, that 
protect the integrity of the homodimer; variations here prevent the formation of 
heterodimers with other alcohol dehydrogenase enzymes.65-66 The dimeric structure and 
the dimeric interface of human GSNOR is shown in Figure 2.2.1b, while the amino acids 
involved in the binding of the zinc atoms are displayed in Figure 2.2.1c.  
These amino acid labels are consistent with the Met1-Ile374 sequence for human 
GSNOR used for the recombinant wild type GSNOR sequenced for this project. The full 
sequence can be found in Appendix Figure A.1.  
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Figure 2.2.1b: GSNOR dimeric crystal structures. GSNOR crystal structure images 
(PDB ID: 3QJ5) modified using UCSF Chimera software. Dimerized wild type GSNOR 
crystal structure. Red circles highlight structural zinc atoms, blue circles highlight catalytic 
zinc atoms. The left-sided monomer is shaded grey to call attention to the dimer interface 
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(i) 
 
(ii) 
 
Figure 2.2.1c: Zinc binding of GSNOR.  
(i) Active site pocket with catalytic zinc. Cys45, His67, Glu68, and Cys174 are 
highlighted. Image acquired from the left-sided monomer, relative to the structures 
displayed in Figure 2.2.1b. 
(ii) Structural zinc with Cys97, Cys100, Cys103, and Cys111 highlighted. Image 
acquired from the left-sided monomer, relative to the structures displayed in Figure 
2.2.1b.  
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2.2.2 GSNO & GSNOR in the Human Body 
The two best substrates for ADH5 are HMGSH and GSNO. With the catalytic 
efficiency of the metabolism of GSNO almost twice of that for HMGSH, GSNO is 
considered the best substrate for the enzyme.67 
The metabolism of GSNO begins with the reductase activity of GSNOR. The first 
step involves GSNOR reducing GSNO to the unstable intermediate N-hydroxy-
sulphenamide (GSNHOH) (Equation 2.2.2a). When GSH is present, GSNHOH will react 
to form the glutathione dimer GSSG, with hydroxylamine (NH2OH) as a side product 
(Equation 2.2.2b). Without GSH present, the unstable GSNHOH will spontaneously 
rearrange to form glutathione sulphinamide (GSONH2) which can then be hydrolysed 
under acidic conditions to obtain glutathione sulphinic acid (GSOOH) and ammonia 
(NH4
+) (Equation 2.2.2c).68 The overall reaction is irreversible67, and the structural 
changes described are shown in Figure 2.2.2a. 
Equation 2.2.2a: 𝑮𝑺𝑵𝑶 +𝑵𝑨𝑫𝑯+𝑯+
𝑮𝑺𝑵𝑶𝑹
→    𝑮𝑺 − 𝑵𝑯𝑶𝑯+𝑵𝑨𝑫+ 
Equation 2.2.2b: 𝑮𝑺 − 𝑵𝑯𝑶𝑯+ 𝑮𝑺𝑯
               
→    𝑮𝑺𝑺𝑮 + 𝑵𝑯𝟐𝑶𝑯 
Equation 2.2.2c: 𝑮𝑺𝑶𝑵𝑯𝟐 +𝑯𝟐𝑶
               
→    𝑮𝑺𝑶𝑶𝑯+𝑵𝑯𝟒
+ 
  
55 
 
 
 
Figure 2.2.2a: Reaction products of GSNO metabolism. GSNO is reduced to GSNHOH 
by enzyme GSNOR and cofactor NADH. Unstable GSNHOH has two routes of action, 
with GSH present, GSSG will be formed. Without GSH, GSNHOH will rearrange to 
GSONH2 which can hydrolyse under acidic conditions to GSOOH. 
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The GNSO products are determined on the cell redox potential related to the GSH 
levels. GSH levels can vary wildly due to its antioxidant activity, under oxidative stress 
GSH levels are decreased.68 This results in GSONH2 and subsequently GSOOH. Under 
physiological conditions, GSH occurring in the millimolar range can result in the formation 
of GSSG and NH2OH.
39 
As previously stated, the regulation of GSNO correlates to cellular NO 
homeostasis, S-nitrosothiol formation, and the formation of reactive nitrogen species 
(RNS). This is due to GSNO acting as endogenous ‘sink’ or ‘reservoir’ of bioavailable NO. 
While NO production by NOS enzymes are co-localized with target proteins, the transfer 
of NO groups to on cysteine residues allows NO to propagate signal transduction pathways 
throughout the cell.69 As GSNO is the most abundant small molecular weight SNO, its 
metabolism by GNSOR is of high consequence.  
In particular, the inflammatory lung diseases of cystic fibrosis and asthma are both 
worsened by the upregulation in GSNOR activity. This, in turn, reduces the bioavailable 
NO in the form of reduced GSNO. Indeed, in GSNOR knockout mice display enhanced 
levels of SNO-proteins while attenuating experimental allergen-induced airway 
hyperreactivity (asthma) and myocardial infarction (heart attacks), at the cost of endotoxic 
shock being more severe.69 GSNOR plays a role in regulating airway smooth muscle tone, 
as well as receptors in lungs and heart.70 As well, they display increased angiogenesis, 
altered homeostasis of G protein–coupled receptors and decreased vascular resistance; due 
to the increase in SNO proteins.69 Single-nucleotide polymorphism in GSNOR have been 
discovered to be are linked with the increase or decrease of childhood asthma, while adult 
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asthma is due to an increase GSNOR of levels and activity in the fluid of the airway 
lining.69 Beyond heart failure and asthma, GSNO has been linked to other diseases as well, 
including Crohn’s disease, IBS, autoimmune encephalomyelitis, autoimmune 
uveoretinitis, and more.69 
2.2.3 Inhibitor’s of GSNOR 
The regulatory processes GSNOR are currently under investigation, with inhibitors 
in particular being highly sought after. Due to dysregulation of GSNOR and GSNO 
depletion is associated with various disease conditions, being able to control activity of 
GSNOR in vivo is of interest.71 
Perhaps the most prolific advancement in GSNOR medicine, is the development of 
Cavosonstat (N91115), a GSNOR inhibitor to aid cystic fibrosis patients with the ΔF508-
CFTR mutation. This is a mutation within the gene for the cystic fibrosis transmembrane 
conductance regulator (CFTR), and is responsible for two thirds of cystic fibrosis cases 
world wide.72 N91115 works to inhibit GSNOR so GSNO is available to promote CFTR 
maturation and plasma membrane stability.73 With an increase in GSNOR activity and 
expression, there is less GSNO available to propagate protein-SNO signaling. Increasing 
the in vivo levels of S-nitrosothiol’s aids to modulate dilation of the airways, and the 
proteins that work to degrade CFTR.73 
The increase in NO bioavailability by inhibiting GSNOR benefits other disease 
states as well. Vascular disorders in particular. N6022 is another inhibitor that made it to 
clinical studies. As a tight-binding, specific, and reversible N6022 is a potent inhibitor that 
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has applications with asthma, chronic obstructive pulmonary disease, and IBS.74 Another 
inhibitor, N6338, has been found to reduce blood pressure and vascular resistance in 
hypertensive rats.75 There are other novel inhibitors70, 74 that have been developed, 
however, N91115 and N6022 have had the most success. 
Recent research has also found GSNOR to be influenced by S-nitrosylation. One 
2016 study found that the nitrosation of conserved cysteines downregulated the enzyme.65 
A reactive oxygen species (ROS)-mediated inhibition of GSNOR has also be discovered.76 
Peroxide treatments led to oxidative modifications on the structural zinc, decreasing the 
rate of GSNO metabolism and contributing to the activation of anti-oxidative mechanisms. 
2.2.4 Deviations & Classical Enzymatic Kinetics 
The rates of reactions for enzymatic processes can be monitored and explained 
through various kinetic parameters over the course of a reaction. A general reaction 
scheme, Equation 2.2.4a describes a reversable joining of the enzyme (E) and the substrate 
(S), to form an enzyme-substrate complex (ES), along with the forward (k1) and reverse 
rates (k-1) of reaction. For the progress of the reaction to come to completion, the ES 
complex performs its function in order to release the reaction product (P); this corresponds 
to its own rate (k2).
77 
Equation 2.2.4a:  
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The classical model to describe enzyme kinetics was described by and named after 
Leonor Michaelis and Maud Menten. The Michaelis-Menten model describes the rate 
equation for the process shown in Equation 2.2.4a as a function of substrate concentration. 
The rate equation, Equation 2.2.4b, demands several assumptions for the fit to be a perfect 
match for experimental data. This includes an assumption for instantaneous chemical 
equilibrium during the formation of ES (k-1 >> k2), as well as the use of steady state 
conditions ([S] >> [E]).77 
Equation 2.2.4b: 𝒗𝒐 = 
𝑽𝒎𝒂𝒙[𝑺]
𝑲𝑴 + [𝑺]
= 
𝒌𝒄𝒂𝒕[𝑬]𝑻[𝑺]
𝑲𝑴 + [𝑺]
  
Upon first glance of the Michaelis-Menten equation (Equation 2.2.4b), three 
parameters present themselves, while others can be derived. The Michaelis constant (KM) 
is derived from the combination of rates displayed in Equation 2.2.4a. This is shown in 
Equation 2.2.4c, operationally KM corresponds to the concentration of substrate at half the 
maximal velocity (Vmax). At the maximal velocity, [S] >> KM and the reaction velocity 
equation can be represented by using k2[E] instead of Vmax, under these conditions, k2 
represents kcat, the catalytic constant. This constant is then used to measure the catalytic 
efficiency, or turnover number, of the system (Equation 2.2.4d).77-78 The catalytic constant 
is defined in Equation 2.2.4e. 
Equation 2.2.4c: 𝑲𝑴 =
𝒌−𝟏+ 𝒌𝟐
𝒌𝟏
 
Equation 2.2.4d: 𝑪𝒂𝒕𝒂𝒍𝒚𝒕𝒊𝒄 𝑬𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚 =  
𝒌𝒄𝒂𝒕
𝑲𝑴
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Equation 2.2.4e: 𝒌𝒄𝒂𝒕 = 
𝑽𝒎𝒂𝒙
[𝑬]
  
Deviations from the Michaelis-Menten model require further consideration in order 
to accurately represent the enzymatic system. Such is the case for allosteric enzymes. The 
term allosteric describes enzymes that have integrations at a site other than the catalytic 
site that influences activity.78 Allosteric modulators can include external ligands or the 
substrate itself and can offer a variety of effects. Binding of a modulator can affect the 
binding affinity of the substrate, affect the rates of the catalysis, or offer conformational 
changes.78 When the binding at an allosteric site affects the binding to the active site, this 
is called a cooperative process, which can proceed in a positive or negative manner. These 
changes affect the steady-state kinetic trend, offering deviations from the Michaelis-
Menten curve. While non-allosteric enzymes form a rectangular hyperbolic curve, 
cooperative binding results in sigmoidal curves depending on the degree of cooperativity.  
A sigmoidal deviation in the O2 binding curve of haemoglobin was first described 
by Archibald Hill.77 The resulting Hill Equation (Equation 2.2.4f) can be used to provide 
a more accurate fit for cooperative steady state kinetic data. A couple of marked differences 
differentiates the Hill Equation from the Michaelis-Menten curve, including the inclusion 
of the Hill constant, n, and the renaming of KM to K0.5. The Hill constant, n, provides the 
degree of cooperativity, when n=1 there is noncooperative behaviour and the curve is 
identical to a Michaelis-Menten plot. With n<1 there is noncooperative allostery and n>1 
corresponds to positive cooperativity with allosteric binding.  
Equation 2.2.4f: 𝒗𝒐 = 
𝑽𝒎𝒂𝒙[𝑺]
𝒏
𝑲𝟎.𝟓
𝒏  + [𝑺]𝒏
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Deviations from Michaelis-Menten resulting in positive cooperativity is shown in 
Figure 2.2.4a, while deviations resulting in various degrees of positive and negative 
cooperativity is shown in Figure 2.2.4b. With a positive modulator (n>1), binding of the 
modulator enhances further binding of the substrate, resulting in a large increase in reaction 
velocity after K0.5, allowing the enzyme to reach Vmax faster. At low substrate 
concentrations, below K0.5, the enzyme is in a less active confirmation, resulting in lower 
reaction rates in comparison to a noncooperative enzyme adhering to similar parameters. 
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Figure 2.2.4a: Classical Michaelis-Menten curve in comparison to a Hill plot 
displaying positive cooperativity. Constructed with identical Vmax and KM=K0.5. n=2 for 
the Hill plot, n=1 for the Michaelis-Menten curve. 
 
Figure 2.2.4b: Various sigmoidal Hill plots. Constructed using various hill coefficients 
(n), and identical Vmax and K0.5 values. Positive cooperativity is shown in the green (n=4) 
and purple (n=2) curves, noncooperatively in the red (n=1) curve and negative 
cooperativity in the yellow (n=0.5), and blue (n=0.25) curves.  
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2.2.5 Electrospray Ionisation Mass Spectrometry (ESI-MS) 
Mass spectrometry (MS) allows for the analytical analysis of molecular ions. It is 
an invaluable tool to identify, characterize, and quantify biomolecules.79 Electrospray 
ionization (ESI) was adapted for tandem use with mass spectrometry in the 1960s, but it 
was not until the mid 1980s when the technique was adapted for use with proteins and 
peptides.80-82 Advancements in this field aided greatly in the advancements in proteomic 
studies.79 The 2002 Nobel Prize in Chemistry was split by John Fenn, for his work on ESI-
MS.  
There are several steps involved in obtaining ionized analyte. The liquid sample, 
prepared in a volatile solvent, is fed through a metal capillary held at a high electric 
potential (2-6 kV). This current can be positive (+, protonation) or negative (-, 
deprotonation) depending on the ion mode of the mass spectrometer. In positive ion mode, 
the analyte will acquire net positive charges. With application of the current, these 
positively charged ions gather at the tip of the capillary, forming a sharp ‘Taylor’ cone.83 
When electrostatic repulsion becomes stronger than the surface tension, charged droplets 
leave the cone the direction of the counter-electrode.84 During the flight, solvent evaporates 
the particles get smaller in size, leading to larger charge densities.82 A flow of nebulizing 
gas (N2(g), as shown in Figure 2.2.5a) adds shear forces to the droplets, aiding in 
disintegration.84-85 With this deformation and reduction in size, and the increase in 
electrostatic repulsion, the particle reaches its upper Rayleigh stability limit, resulting in a 
‘Rayleigh explosion’ where the larger ‘parent’ particle surface turns into a protrusion 
wherein the particle gives off a jet of ‘daughter’ microdroplets.84 This process continues 
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until only bare ions remain. It is bare ions of interest that are completely sorted by their 
mass charge (m/z) ratios and detected by the spectrometer.  
  
  
65 
 
 
 
Figure 2.2.5a: Electrospray ionization of liquid analyte. With a high electric potential 
applied to the analyte capillary, the otherwise round meniscus forms a cone where charges 
collect (in this case, positive charges, for the application of a positive potential). Analyte 
is released as fine mist to enter the mass spectrometer. As charged droplets enter the 
counter-electrode, flowing through pressure and potential gradients aids in stripping ions 
of solvent and of each other, allowing only bare ions be detected.  
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2.2.6 Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS) 
Hydrogen/deuterium exchange (HDX) mass spectrometry (MS) is a technique that 
has become key in investigating the structural dynamics of a protein structures. This is 
significant knowledge, to supplement the information that static structures obtained from 
crystal structures.86 As well this technique can offer insights to protein-protein complexes, 
protein-ligand interaction, protein mutations, post-translational modifications, and monitor 
conformational changes due to functional changes.87 The pharmaceutical industry, in 
particular, benefits from HDX-MS, in regards to protein-drug interactions.87 
The exchange reaction occurs when a deuterium source is introduced to a protein 
solution. Labile protons will exchange with the solvent, including -OH, -NH, and -SH 
hydrogens.86 However, since the hydrogens of amino acid side chains can exchange on a 
sub-millisecond time scale, most studies are concerned with the slower exchange that can 
be monitored on peptide backbone amides.86, 88 Of the backbone amides, exchange is faster 
on fully solvent exposed amides that are not involved in hydrogen bonding. 
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Figure 2.2.6a: Hydrogen/deuterium exchange (HDX) with parallel β-sheets. Solvent 
exposed, non-hydrogen bonding amide hydrogens will readily exchange with introduced 
deuterium. Atoms involved in the change are showed in blue. 
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 The exchange rate of any given amide is dependent on the rate constant of the 
chemical exchange (kch), combined with the rates of open (kop) and closed (kcl) confirmation 
transitions of the amide.86 kch is influenced by the flanking side changes, reaction 
temperature, and deuterium ion concentration (pD). The mechanism detailing the opening 
of a closed amide, the deuterium exchange, and the return to a closed confirmation is shown 
in Equation 2.2.6a.86 The rate of overall exchange (kHDX) can then be described as a 
combination of these rates, with three possibilities: (1) If the rate of H to D change (kch) is 
much greater than the rate of the amide closing (kcl), (kch >> kcl), then Equation 2.2.6b is 
the simplified rate equation. This implies that exchange occurs during the first opening 
event.86 (2) If the rate of closure (kcl) is much greater than the rate of the exchange (kch), 
(kch << kcl), then Equation 2.2.6c is the simplified rate equation. This situation is more 
common under physiological conditions. (3) If the amide is permanently unprotected, 
Equation 2.2.6d is the simplified rate equation.86 
Equation 2.2.6a:  
Equation 2.2.6b: 𝒌𝑯𝑫𝑿 = 𝒌𝒐𝒑 
Equation 2.2.6c: 𝒌𝑯𝑫𝑿 = 
𝒌𝒐𝒑
𝒌𝒄𝒍
𝒌𝒄𝒉 
Equation 2.2.6d: 𝒌𝑯𝑫𝑿 ≈ 𝒌𝒄𝒉 
The exchange reaction can be acid, base, or water catalyzed, with the acid catalyzed 
mechanism predomination at pH’s below 2. At pH levels between 2.0-3.0, water catalysis 
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is dominant, with acid and base mechanisms contributing equally.89 It is here where the 
exchange rate (kch) is at its lowest, with values 10,000-fold lower at pH 2.5, compared to 
pH 7.0.89-90 
HDX-MS experiments are capable of investigating protein-substrate interactions. 
One method of doing so includes utilizing microfluidic set ups in order to perform 
consistent and reproducible experiments. An example of this is the time-resolved 
electrospray (TRESI) microfluidics set up developed by Wilson and Konermann.91 In a 
quench-flow experiment, the exchange reaction is initiated by the rapid mixing of reagent, 
and concluded by mixing with a quenching reagent. The TRESI device contains a series of 
capillaries with an adjustable reaction volume that allows for static time-points and kinetic 
measurements. The basis of the set up includes a larger metal capillary with a smaller glass 
capillary inside. When the ends of the two are flush, the reaction volume is zero. When the 
glass capillary is pulled deeper into the metal capillary, the reagents being pumped through 
the two capillaries are allowed to mix. Protein solution flowing through the glass capillary 
is mixed with deuterium oxide flowing around the glass, contained by the metal capillary. 
The mixing volume, adjustable by the movement of the glass capillary, ends at a T-
junction, in which the solution is mixed with an opposite flow of quenching solution (acid). 
The quenched reaction exits out the perpendicular channel, towards the ionization source 
(ESI).  
In this study, the enzyme S-nitrosoglutathione reductase (GSNOR) is characterized 
computational studies, kinetic studies, and hydrogen deuterium exchange mass 
spectrometry. These studies may support the existence of a possible allosteric site on the 
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enzyme. Further information on the HDX experiments performed here, as well as the use 
and set up of the TRESI device is elaborated on in the Methods section of this chapter, in 
Section 2.3.8, and Figure 2.3.8a in particular. 
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2.3 Methods 
2.3.1 GSNOR WT Cloning, Mutagenesis, and Protein Isolation 
 The original cloning and mutagenesis of the human ADH5 gene was performed by 
Dr. Bei Sun. The final result was recombinant GSNOR containing two 6X-histidine tags, 
one at each terminus, to aid in purification. The pET28b_ADH5 plasmid was then 
transformed into BL21(DE3) E. coli for further work. Further detail on Dr. Sun’s work in 
this regard can be found in Appendix A. 
To begin protein isolation, a single pET28b_ADH5 in BL21 cellular colony was 
picked from LB-kanamycin agar plates and grown in a sterile round bottom polypropylene 
culture tube containing 4 mL of 2X YT media and 50 μg/mL kanamycin (YT kan); this 
was left to incubate overnight at 37⁰C with shaking. This colony of cells was added to a 
starter culture flask at a rate of 1 mL of colony per 100 mL of YT kan media; this was 
grown for 8 hours at 37⁰C with shaking. This starter culture was used to inoculate 1 L of 
YT kan media in a 4 L flask, at the same rate of 1 mL per 100 mL of media. This was then 
left to grow overnight, shaking at room temperature. The next morning, GSNOR 
expression was induced by the addition of IPTG to a final concentration of 0.4 mM. This 
induced culture was left to incubate for 24 hours, shaking, at room temperature. The cells 
were then harvested by centrifugation, the cells and their media were placed in 500 mL 
Nalgene centrifuge bottles and centrifuged at 6,000 rpm for 30 minutes at 4⁰C. The 
supernatant was subsequently discarded and the bacterial cell pellet was resuspended in pH 
8 lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM PMSF, 1% Triton X-100, 75 μg/mL 
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DNase I and 100 μg/mL lysozyme). The crude lysate was incubated on ice for 30 minutes 
and further lysed by pulse sonication. This was done on ice, with 30 seconds on, 30 seconds 
off, for a total of 8 pulses. The lysate was then centrifuged in 50 mL Nalgene centrifuge 
bottles at 12,000 rpm for 30 minutes at 4⁰C. Further purification of the supernatant was 
done using HIS-Select Nickle Affinity Gel (Sigma-Aldrich P6611).  
 The Ni affinity column, stored in 20% (v/v) ethanol, was equilibrated with wash 
buffer (50 mM Tris-HCl, 150 mM NaCl, pH 8) and placed in a 50 mL conical tube. The 
lysate supernatant was added to the column matrix and allowed to mix for 1 hour at 4⁰C. 
The lysate and matrix were returned to the glass chromatography column (Rio-Rad Econo-
Column). The column matrix was washed with wash buffer, followed by 10 mM imidazole 
wash buffer, and then 25 mM imidazole wash buffer before elution. Bound GSNOR was 
then eluted with elution buffer (300 mM imidazole, 50 mM Tris-HCl, 150 mM NaCl, pH 
8). The eluted protein was then buffer exchanged into storage solution (58 mM Na2HPO4, 
17 mM NaH2PO4, 68 mM NaCl, 15% glycerol, pH 7.4) using 15 mL capacity Amicon 
centrifugal filter tubes (Millipore Sigma UFC903008) and stored at -80°C.  
2.3.2 GSNO Synthesis 
 The majority of the GSNO used for this project was synthesized by Leslie 
Ventimiglia and Mark Potter.  
GSNO was synthesized in-house as per previously determined protocols.92 
Glutathione (GSH) was mixed in a 1:1 stoichiometric ratio of sodium nitrite (NaNO2) at 
4⁰C in 0.5M HCl. After 40 minutes, acetone was added in 1:1 (v/v) and mixed for 10 
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minutes until the red GSNO precipitated out of solution. The precipitate was subsequently 
filtered and washed 3x with cold water, 3x acetone, and 3x ether. The GSNO was then 
lyophilized and stored at -20⁰C. The concentration of any GSNO solution prepared out of 
the lyophilized powder was confirmed by UV-Vis spectroscopy; as outlined in Section 
2.3.3. 
 
Figure 2.3.2a: Synthesis of GSNO.  
2.3.3 GSNOR WT Kinetics & Kinetic Parameters 
 Steady state kinetic assays were performed using GSNO as a variable substrate, and 
keeping cofactor NADH constant. 20 mM NADH stock solution was prepared with Milli-
Q (Advantage A10 Water Purification System, Millipore Sigma). GSNO stock solutions 
were prepared fresh from lyophilized powder and pH 7.4 PBS into 10 mM and 1 mM stock 
solutions. The true concentration of GSNO was obtained by measuring the absorbance of 
the 1 mM solution at 335 nm, utilizing the molar extinction coefficient of 922 M-1 cm-1, 
and Beer’s Law.93 
 GSNO, of increasing concentrations was added to a 500 μL cuvette containing 80 
μM NADH and pH 7.4 PBS to a final volume of 500 μL. The kinetic reaction was initiated 
by the addition of 2 μg of GSNOR. The concentration of stock GSNO was confirmed by 
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Bradford Assay immediately prior to the experiment. The uptake of NADH during the 
reaction was monitored by its decrease in absorbance at 340 nm, 60 seconds of reaction 
was monitored by the Agilent 8453 UV/Vis spectrophotometer. The rate of the initial linear 
decrease corresponding to NADH uptake was plotted in correlation to the concentration of 
GSNO. From this, K0.5 and Vmax were calculated. Catalytic efficiency and kcat were 
determined utilizing Equations 2.2.4d-e, respectively. 
The experimental kinetic data was manipulated and plotted as per Equation 2.3.3a-
b to determine the Hill constant. The constant, n, was found as the slope of the resulting 
line of best fit. This is due to the fact that the manipulation performed results in a graph 
displaying Equation 2.3.3c, where K represents binding constants of the ligand. 
Equation 2.3.3a: 𝒙 − 𝒗𝒂𝒍𝒖𝒆𝒔 = 𝐥𝐨𝐠(𝑿) = 𝐥𝐨𝐠 ([𝑮𝑺𝑵𝑶]) 
Equation 2.3.3b: 𝒚 − 𝒗𝒂𝒍𝒖𝒆𝒔 = 𝐥𝐨𝐠 (
𝒀
𝟏−𝒀
) =  𝐥𝐨𝐠 (
𝒚
𝑽𝒎𝒂𝒙
𝟏−
𝒚
𝑽𝒎𝒂𝒙
)  
Equation 2.3.3c: 𝒍𝒐𝒈 (
𝒀
𝟏−𝒀
) = 𝒏 𝐥𝐨𝐠(𝑿) + 𝐥𝐨𝐠 (𝑲) 
2.3.4 Mass Spectrometry (MS) 
 All mass spectrometry was performed at York University in Toronto, Ontario in 
collaboration with Dr. Derek J. Wilson and his Lab Manager Cristina Lento. All 
experiments were performed by the author on a Waters Synapt G1 High Definition Mass 
Spectrometer (Synapt G1) with an electrospray ionization (ESI-MS), schematic shown in 
Figure 2.3.4a. The Synapt G1 utilizes Waters’ Triwave™ technology to allow for ion 
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mobility separation (IMS); adding the separation based on mass and size to a given data 
set. With the IMS function turned on, unresolved, overlapping, peaks can be separated and 
analyzed. Analyte enters the mass spectrometer through electrospray ionization (ESI). Ion 
obtain a net positive charge through the application of a positive potential electric field. 
The formation of charged droplets results in solvent evaporation and gas-phase ions of 
interest. Electrostatic attraction and a vacuum allow the ions to enter into the spectrometer. 
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Figure 2.3.4a: Waters Synapt G1 Definition Mass Spectrometer schematic. Analyte is 
ionized from an electrospray source and incoming ions are focused by the T-wave ion guide 
mass ion selection by the quadrupole. The Triwave™ technology works with three ‘waves’ 
that perform three distinct functions: the first wave traps and releases ions, the second 
separates ions by their ion mobility and the final wave transfers ions to the time of flight 
(TOF) mass analyzer. Further fragmentation by collision induced dissociation (CID) can 
be performed before or after ion mobility separation. 
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2.3.5 GSNOR WT Native MS 
 Purified recombinant GSNOR was dethawed and storage buffer was buffer 
exchanged with 200 mM ammonium acetate, using a 15 mL compacity Amicon centrifugal 
filter tube. Protein was injected into the Synapt G1 mass spectrometer at a rate of 6 μL/min 
and data was recorded in positive ion mode at a range of 500-8000 m/z. Other system 
settings are overviewed in Table 2.3.5. The electrospray voltage settings are consistent for 
all MS data sets.  
Table 2.3.5: Native GSNOR Synapt G1 Operating Settings. 
Electrospray Ion Source Voltage Settings 
Capillary Voltage 3.00 kV 
Sampling Cone 50 V 
Extraction Cone 2.0 V 
Operating Pressures (Torr) 
Trap 1.06 x 10-2  
IMS Cell 5.22 x 10-4  
TOF 7.63 x 10-7  
Backing Pressure 2.22 
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2.3.6 GSNOR WT Peptide Fragmentation 
MS1 fragmentation of native GSNOR WT is done using pepsin agarose beads 
placed in a fabricated poly(methyl methacrylate) (PMMA) chip that allows for low-
pressure proteolysis with on-chip ESI. Fabricated as previously described by Wilson and 
colleagues.94 The PMMA chip is shown in Figure 2.3.6a (i) while the assembled 
microfluidics apparatus is shown in Figure 2.3.6a (ii); this set up includes the blue-
coloured pepsin agarose beads, the entrance connector carrying native protein, ready for 
proteolysis, and an exit channel, towards ionization by electrospray and analysis by the 
Synapt G1 MS. The stock aliquots of pepsin agarose beads used are maintained by the 
Wilson Lab.  
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(i) 
 
(ii) 
 
Figure 2.3.6a: PMMA chip for protein proteolysis. 
(i) PMMA chip, with entrance channel and an exit channel, connected by the 
proteolysis reaction chamber. 
(ii) Native protein solution is pumped into the PMMA microfluidics chip containing 
pepsin agarose beads for low-pressure proteolysis. The peptides then exit the pepsin 
resin for ESI to enter the Synapt G1 spectrometer.  
Pepsin Agarose Beads Positive Electric 
Potential (3 kV) 
Native Protein Solution Microfluidics Chip Peptides to MS 
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2.3.7 GSNOR WT MS-MS for Peptide Identification 
  Tandem mass spectrometry (MS-MS, or MS2) is utilized for characterization of the 
peptides fragmented from the pepsin column. By acquiring data in MS-TOF mode, a 
precursor ion can be chosen to undergo further fragmentation by CID. The collision energy 
applied was customized for each precursor ion to obtain an ideal fragmentation pattern. 
The fingerprint spectra were collected within a mass range of 100-2000 m/z.  
A theoretical pepsin digest was performed using FindPept tool on the ExPASy 
Proteomics server (Swiss Institute of Bioinformatics, Basel). Search parameters were set 
to pepsin (porcine A) at pH > 2 with a mass tolerance of ± 0.5 Da. The possible identities 
of the parent ion were chosen from the resulting list. Each possible parent ion was 
theoretically fragmented by the spectra viewing software mMass and compared with the 
fingerprint. The parameters used included searching for the loss of -H2O and -NH3, as well 
as identifying y, a, b, int-a, and int-b fragment ions.  
2.3.8 GSNOR WT HDX-MS 
 Hydrogen deuterium exchange (HDX) MS was made possible by outfitting the 
Synapt G1 with the custom TRESI apparatus as described by Wilson et al.91 The reagents 
utilized include 5% (v/v) acetic acid, GSNOR in 200 mM ammonium acetate, and 
deuterium oxide (D2O) (99.9% purity of LC-MS grade, Sigma-Aldrich). These reagents 
are pumped through polyamide-coated glass capillary with an outer diameter (o.d.) of 109.2 
μm using Harvard Apparatus Pump 11 Elite infusion syringe pumps (Holliston, MA). 
Protein and D2O were pumped at a rate of 2 μL/min with 0.5 mL syringes (Hamilton 700 
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Series Gastight Syringe) while acid was pumped at a rate of 16 μL/min with a 5 mL or 2.5 
mL syringe (Hamilton 1000 Series Gastight Syringe). 
 The TRESI microfluidics apparatus describes where the mixing of protein and D2O 
takes place. The 109.2 μm o.d. glass capillary containing protein is encased in a metal 
capillary with an inner diameter (i.d.) of 132.6 µm. A 2 mm notch was made and the end 
of the glass capillary was sealed, this allowed for efficient kinetic mixing before the 
exchange reaction was quenched by the acid and sent to the PMMA chip containing the 
pepsin agarose beads for MS1 fragmentation. The creation of the notch and the melting the 
end of the glass capillary was done fresh for each experiment using a VersaLaser™ as 
described.91 Measuring different time points of D2O incorporation is done by measuring 
the distance allowed from the end of the ‘plug’ (Figure 2.3.8a (i)) to the end of the outer 
capillary. The schematic of this device and its physical manifestation is shown in Figure 
2.3.8a. 
The HDX-MS experiments conducted for this report utilized 5 mm and 10 mm 
reaction spaces, which corresponds to 2.07 seconds (~2 secs) and 3.93 seconds (~4 secs), 
respectively. Data was collected in IMS mode in the 400-1500 m/z range. The operational 
settings and average operational pressures for these experiments are summarized in Table 
2.3.8. The experimental deuterium uptake of each peptide obtained was calculated using a 
custom-built software program (DJW, unpublished results). 
Each set of data was collected on the same day, including three 5 min spectra 
acquisitions of: protein GSNOR without deuterium exchange, two secs exchange, and four 
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secs exchange. Followed by three 5 min spectra acquisitions of: protein GSNOR + 20x 
excess of GSNO without deuterium exchange, two secs exchange, and four secs exchange. 
Concentrations of GSNOR and GSNO were calculated by Bradford assay and UV-Vis, 
respectively, to confirm a 20x stoichiometric addition of GSNO. Integrity of the notch was 
confirmed to be maintained at the end of the experiment.  
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(i) 
 
(ii) 
 
Figure 2.3.8a: TRESI microfluidics set up for HDX-MS. 
(i) Schematic for D2O and protein mixing, followed by acid quenching and 
fragmentation by pepsin. Protein solution exits the notch and immediately mixes 
with D2O, the space from the end of the glass inner capillary to the end of the metal 
outer capillary corresponds to the exchange reaction time.  
(ii) Complete set up of the TRESI device connected to the PMMA chip. 
Acid 
Protein 
D
2
O 
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Table 2.3.8: HDX-MS GSNOR Synapt G1 Operating Settings. 
Electrospray Ion Source Voltage Settings 
Capillary Voltage 3.00 kV 
Sampling Cone 50 V 
Extraction Cone 1.5 V 
Operating Pressures (Torr) 
Trap 2.19 ± 0.15 x 10-2  
IMS Cell 5.66 ± 0.37 x 10-1  
TOF 7.99 ± 0.22 x 10-7  
Backing Pressure 2.17 ± 0.05 
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2.4 Results  
 Sigmoidal deviations resulting in positive cooperativity were identified with 
GSNOR kinetics. To further investigate the allosteric effect, molecular docking (MD) 
simulations were performed to look for a possible allosteric binding site for substrate 
GSNO. Electrospray mass spectrometry (ESI-MS) was also utilized it identify protein-
ligand interactions. The MS experiments performed here include: native MS for dimer 
identification, MS-MS for peptide identification, and hydrogen–deuterium exchange 
experiments (HDX-MS) for the investigation of direct ligand interactions. 
2.4.1 GSNOR WT Kinetics 
 Steady state kinetic assays of recombinant wild type GSNOR were performed in 
triplicate, with one set of representative data being displayed throughout this section. Upon 
assessment of the kinetic parameters of GSNOR, the apparent KM, or K0.5, was 16.7 ± 0.53 
μM towards GSNO with a kcat of 120000 ± 40000 s-1. The catalytic efficiency, calculated 
as kcat/K0.5, was found to be 12000 ± 2000 s
-1 M-1. These values, as well as the Hill constant 
(n), are summarized in Table 2.4.1.  
To determine possible allostery, the Hill coefficient was deduced to quantitatively 
determine the cooperativity of ligand binding. The kinetic data for reactions containing 0-
70 μM GSNO were used to construct a Hill plot, as shown in Figure 2.4.1a. The resulting 
Hill constant observed was 1.49 ± 0.037.  
 With the Hill constant calculated, fit curves can be applied to the experimental data, 
as in Figure 2.4.1b (i-ii). The featured data is shown with the classical Michaelis-Menten 
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curve (n = 1) as well as the corresponding Hill plot (n = 1.54). Figure 2.4.1b (ii) offers a 
closer look at the lower concentrations. 
Table 2.4.1: GSNOR WT Kinetic Parameters.  
Kinetic Parameter Value 
K0.5 (μM) (n=3) 16.7 ± 0.53 
kcat (x10
5 s-1) (n=3) 1.2 ± 0.4 
kcat/K0.5 (x10
4 s-1 M-1) (n=3) 1.2 ± 0.2 
n (n=3) 1.49 ± 0.037 
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Figure 2.4.1a: Hill plot for the discovery of the Hill constant (n). Utilizing 
representative data of 0-60 μM GSNO, the Hill constant is determined by the slope of the 
line of best fit, n = 1.54. 
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(i) 
 
(ii) 
 
Figure 2.4.1b: Representative GSNOR WT kinetic data. Initial reaction rates measured 
by monitoring the decrease in absorbance at 340 nm. Each reaction contained 80 μM of 
NADH and was initiated by the addition of 2 μg of enzyme. Error bars represent standard 
deviation (n=3). Displayed is a Michaelis-Menten fit curve (K0.5 = 16.8 μM, n = 1, blue 
dashed curve) contrasted with a Hill plot (K0.5 = 16.8 μM, n = 1.54, solid red curve). 
(i) Substrate range: 0-200 μM GSNO. 
(ii) Substrate range: 0-60 μM GSNO.  
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2.4.2 Native GSNOR WT MS 
 Obtaining the mass spectra for the native protein GSNOR allows for calculation of 
the molecular weight. As well as viewing monomers, dimers, trimers, etc., if applicable. 
Performing this experiment proves that the dimer is involved in the HDX experiments, 
however not the protein solution is not purely dimerized.  
The spectra obtained can be found in the Appendix Figure B.1, with peaks 
corresponding to monomeric GSNOR and dimerized GSNOR. The m/z values for these 
peaks is summarized in Appendix Table B.1. While the monomer peaks display as broad 
and unresolved, each subsequent dimer peak appears as three relatively distinct peaks 
(termed 1st, 2nd, and 3rd from low to high m/z). The molecular weight of these peaks were 
determined using ESIprot Online.95 The results are displayed in Table 2.4.2. The three 
dimer peaks have an average first difference of 635 Da. Since GSNOR is known to carry 
NADH molecules throughout the purification process, this stepwise increase in mass could 
be explained by a dimer set with no NADH, a dimer with one monomer containing NADH, 
and a dimer with both monomers containing NADH. The molecular weight of NADH is 
663 g/mol, which is within the combined errors of each calculated MW.  
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Table 2.4.2: Experimental MW of GSNOR, derived from native MS.  
 Molecular Weight (Da) 
Monomer 43384.06 ± 29.17 
1st Dimer 86285.54 ± 54.54 
2nd Dimer 86944.87 ± 47.89 
3rd Dimer 87554.32 ± 29.43 
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2.4.3 GSNOR WT MS-MS Coverage Map 
 Obtaining identification of each peak in in MS fingerprint is necessary in order to 
produce a heat map of deuterium uptake. Thirty-two MS-MS spectra were obtained and 
successfully matched to peptide fragments of GNSOR. These peptides identified 188 
unique amino acids which corresponds to about 50% sequence coverage. The list of these 
peptides and the corresponding sequence map is displayed in Appendix B. The sequence 
coverage can be extended by successfully matching other MS-MS spectra with the proper 
peptides. As well, incorporating chromatography in the MS process could theoretically 
help to increase the resolution of the peptides and aid in MS-MS data collection.  
2.4.4 Previous Computational Studies 
 Previous molecular dynamics (MD) simulations were conducted in collaboration 
by Dr. B. Sun and Dr. B Mutus with Dr. James Gauld and his student S. Nikoo. These 
studies were performed in order to provide speculation into the possible allosteric binding 
site of GSNO.   
A template crystal structure (PDB ID: 3QJ5) was used to perform the docking 
simulations using Molecular Operating Environment software (MOE, 2013.08; Chemical 
Computing Group Inc. Montréal, QC, Canada).96 The results of the model implicated four 
amino acids in the binding of GSNO at a putative allosteric site. Asn185 and Gly321 
appeared to interact with GSNO directly while Lys188 and Lys323 interacts indirectly, 
through a solvent network of hydrogen bonds. The study also provided docking score; these 
are used to predict binding affinity, with a low score indicating stability and favorable 
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interactions. GSNO binding at the active site gave a score of -8.60 while the putative 
allosteric site has a score of -10.4.96 
 This punitive allosteric binding of GSNO and the implicated amino acid residues 
are displayed in Figure 2.4.4a.  
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Figure 2.4.4a: Putative allosteric site near the structural zinc, as discovered by MD 
simulations. Asn185 and Gly321 are predicated to interact with GSNO directly while 
Lys188 and Lys323 interacts indirectly.  
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2.4.5 GSNOR WT HDX-MS  
The custom TRESI device allowed for two static time points for the deuterium 
exchange reaction to occur; two seconds and four seconds were chosen.  
Of the data obtained, six sets of data describing GSNOR peptides as they respond 
to deuterium incorporation were successfully analyzed. Sample spectra of this data can be 
seen in Appendix D, in Figures D.1-3. Baseline spectra displays peptides in a typical 
fashion of ESI peptides (Figure D.1); with the with the highest intensity peak being the 
first peak and subsequently decreasing in intensity. As deuterium is incorporated (Figure 
D.2-3), the peak distribution shifts with the addition of the heavier isotope. This shift is 
used to observe the overall amount of deuterium that is taken up by the peptide. The next 
layer of data incudes the incorporation of the substrate GSNO. Sample spectra of GSNOR 
+ GNSO data can be seen in Appendix D, in Figures D.4-6. Two sets of GSNOR + GNSO 
HDX data were successfully analyzed.  
Twenty times the concentration of GSNO was mixed in GSNOR, to ensure 
sufficient substrate was available to be observed interacting with the active site, as well as 
the putative allosteric site. While there are some subtle changes that can be viewed between 
the two spectrums’, the most obvious is the appearance of a 613 m/z (z = 1) peak after the 
addition of GSNO. Based off literature MS studies of the GSNOR’s kinetic processes, it is 
most likely that this peak corresponds to GSSG.67 This is not unexpected, since the GSNO 
synthesized in-house was not completely pure, and degrades over time. This would lead to 
GSH being present in the sample used, and is also why the concentration if GSNO used is 
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always confirmed with UV-Vis spectroscopy on the day of use. As well, it is not possible 
to purify GSNOR without residual NADH carried throughout the process. With the 
substrate and the cofactor present, some GSNO would be metabolized by the enzyme, 
leading to GSSG since GSH is present (Figure 2.2.2a). Excess GSNO and GSOOH (if any 
was produced) was not witnessed since both molecular weights are below 400 Da, and thus 
below the threshold of data acquired. 
The results of these HDX-MS experiments are summarized in Appendix D. Table 
D.1 offers a closer look at the peptide (I)PLYIPQCG(E) (residues 91-98). Here, the visible 
change that deuterium incorporation has on the peptide’s peak distribution can be seen. 
Numeric summary of the two second exchange reaction time is displayed in Table D.2 and 
the four second exchange reaction is in Table D.3. These tables provide the baseline 
deuterium uptake (%) for each peptide, which represents GSNOR data without GSNO. As 
well as the deuterium uptake (%) for each peptide with GSNO incorporated. The values of 
consequence, however, is the difference between these two values. Those values are what 
is superimposed on the crystal structures (Figures 2.4.5 (a-b)) to pictorially view the 
response to the presence of GSNO. 
Four amino acid residues were implicated by computational means as being 
involved in the interaction of GSNO at a putative allosteric site; Asn185, Gly321, Lys188, 
and Lys323 (Figure 2.4.4a). While Asn185 is not represented by the identified peptide list, 
Lys188 and Lys323 are, as well as Gly321, which is represented twice. Under a two second 
exchange reaction, these residues all show a decrease in deuterium uptake (Table 2.4.5). 
This is displayed in Figure 2.4.5a, where the decrease in uptake is denoted with increasing 
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shades of red. Areas with the largest decrease in uptake can be seen around this putative 
site, as well as in the active site pocket.  
The results of the two second exchange reaction is at a contrast with the four second 
exchange. With double the time for allowed mixing, the majority of peptides displayed an 
increase in deuterium uptake. The notable exceptions are some peptides around the NADH 
binding region, as well the peripheral peptides in the same area. These peptides, located in 
the lower right quadrant of Figure 2.4.5 (a-b) show remarkedly similar uptake patterns at 
both time points. This exception also includes Lys188, whose peptide displays an uptake 
difference that is more negative than compared to the two second exchange data (Table 
2.4.5). 
Table 2.4.5: Δ Deuterium uptake of the amino acid residues implicated in allosteric 
biding. 
 
2 sec Exchange 
Δ Deuterium 
Uptake (%) 
4 sec Exchange 
Δ Deuterium 
Uptake (%) 
Representing  
Peptide Sequence 
Asn185 N/A N/A N/A 
Gly321 
-0.9 
-1.4 
+0.1 
+0.5 
(W)/KGTAFGGWKS(V) 
(F)/GGWKSVESVPK(L) 
Lys188 -0.4 -0.6 (T)AKLEPGSVC(A) 
Lys323 -1.4 +0.5 (F)/GGWKSVESVPK(L) 
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Δ Deuterium Uptake (%) 
Red Salmon Pink  Sky Blue Blue 
-1.8 -0.7 -0.4 0 0.6 3.4 
Figure 2.4.5a: HDX-MS heat map after two seconds of deuterium exchange. Red 
conveys a decrease in deuterium incorporation after in inclusion of GSNO, Blue conveys 
an increase. The putative allosteric binding site with GSNO is shown, along with labels of 
the implicated resides involved in allosteric binding.  
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Δ Deuterium Uptake (%) 
Red Salmon  Sky Blue Dodger Blue Blue 
-5.2 -0.8 0 0.7 1.4 5.1 
Figure 2.4.5b: HDX-MS heat map after four seconds of deuterium exchange. Red 
conveys a decrease in deuterium incorporation after in inclusion of GSNO, Blue conveys 
an increase. The putative allosteric binding site with GSNO is shown, along with labels of 
the implicated resides involved in allosteric binding.  
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2.5 Discussion 
 In addition to the preliminary computational studies, the enzyme kinetics of 
GSNOR, and HDX-MS studies at two reaction time points have been analyzed in the effort 
of supporting the hypothesis of the existence of an allosteric site.  
2.5.1 GSNOR Kinetics 
 The steady state kinetic assays performed provide a convincing basis for the 
hypothesis of allosteric binding. With a Hill number (n) of 1.49 ± 0.037, there is indication 
of some form of cooperative binding being observed. In addition to this, the Hill Plot curve 
has a far superior fit in comparison to the basic Michaelis-Menten curve (Figure 2.4.1b); 
while utilizing the same values for Vmax and K0.5/KM, which were experimentally derived. 
The Hill Plot can account for the slower rates when approaching K0.5 while also observing 
the faster ascent to Vmax that positive allosteric binding makes possible.  
2.5.2 GSNOR HDX-MS: Two Second Exchange 
Of the residues implicated in allosteric binding, Gly321, Lys188, and Lys323 have 
representing peptides identified by MS-MS. As can be seen in Figure 2.4.5a, these 
residues, and other peptides surrounding the computational placement of GSNO exhibit a 
decrease in deuterium uptake. Gly321, which is represented twice, displays a decrease of 
0.9% and 1.4%, while Lys188 shows on a peptide that decreased of 0.4% and Lys323 
decreased of 1.4%. 
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A decrease in deuterium uptake in peptides leading to the active site pocket, 
peptides involved in binding NADH, and of those binding to the catalytic zinc, was also 
observed. This included the amino acid residues Cys45 (-0.4%, TAVCHTDAYTLSGAD), 
His67 (-0.3%, ILGHEGAGIVESVGEG; -0.7%, GHEGAGIVESVGEGVT), and Glu68 (-
0.3%, ILGHEGAGIVESVGEG; -0.7%, GHEGAGIVESVGEGVT), of which are involved 
in the binding of the catalytic zinc. Observing this decrease in solvent exposure around the 
active site is not unexpected or unwelcome; the fact that GSNO causes a change here adds 
another layer of legitimacy to the observations at the putative site. Further speculation on 
the HDX-MS structure patters can be found in Section 2.5.3. 
The conformation of the structure used to display this data was obtained as a 
computationally minimized structure, followed by an induced fit at the active site.96 The 
consequence of this is that the static image shows the monomer as slightly puckered, in 
comparison to the dimerized crystal structure (PDB ID: 3QJ5). Since Lys188 is the residue 
that displayed a decrease in solvent exposure at both time points, the distance between the 
α-carbon of Lys188 and the structural zinc since was chosen to display the differences in 
confirmation after binding of GSNO. The physical location of the other amino acid residues 
implicated in binding are located between Lys188 and the structural zinc. In the 
computationally untouched dimerized crystal structure, the distances displayed are 24.4 Å 
and 23.2 Å. The monomeric structures of the MD simulations have a shorter distance of 
22.0 Å. Computationally minimized structures of the enzyme with GSNO in the allosteric 
site and active site, as well as just at the active site, while being bound as a dimer would be 
  
101 
 
 
of interest; the further explore the structural effects of the allosteric site. Figure 2.5.3a (iii-
iv) depict these distances. 
Table 2.5.2: Distance between Lys188 and the structural zinc. These distances were 
determined using UCSF Chimera software.  
Structure: 
Distance between Lys188 and structural 
zinc (Å): 
Dimerized crystal structure 24.409, 23.150 
Minimized monomer 22.014 
 
2.5.3 GSNOR HDX-MS: Four Second Exchange 
With double the reaction time, the data obtained from the four second reactions 
move to more extreme changes in the uptake levels. While the two second reactions gave 
peptide changes in the -1.8% to +3.4% range, the four second reactions were found to be 
between -5.2% to +5.1% deuterium uptake change. As well, the majority of the peptides 
presented an increase in uptake levels, with only five peptides in the negative range. To 
counter this, there are also larger standard deviations in the values obtained for each 
peptide; the most extreme peptides on either side both have errors around 4%, easily the 
highest of all the data presented. This is not to negate the obvious trend observed, since 
there is clearly an increase in deuterium uptake across the span of peptides. With a longer 
time for the exchange reaction to occur, more time is present for the D2O to displace the 
ligand-containing solvent surrounding the enzyme. The consequence of this larger time is 
that any observations of ligand interactions is essentially exchanged away. All that can be 
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said for the amino acid Gly321 and Lys323 is that they do not exceed +0.5% change in 
deuterium uptake, while Lys188 exhibits -0.6% uptake.  
 The GSNOR dimer arranges itself with a central axis of β-pleated sheets. The 
regions that continue to display a decrease in deuterium uptake (with similar patterns to the 
two sec exchange data) are placed at each end of this ‘column’ of β-sheets. In the dimerized 
image shown in Figure 2.5.3a (i-ii). One explanation for retention of negative uptake is 
that this section of the protein is less flexible, with more hydrogen bonding, and less likely 
to be affected by the increase in reaction time. It is entirely possible that this is the real 
putative site for GSNO docking, however, it is unlikely that GSNO would display a 
stronger interaction here over the active site.  
The dimerized image in Figure 2.5.3a (iii) offers another perspective of the 
allosteric region; the dimers has been rotated 180⁰ on a horizontal axis, offering a ‘back-
side’ view in comparison to the Figure 2.5.3a (i-ii) orientation. Although the GSNO is not 
shown, the binding regions of the allosteric site are shown by blue ovals. The blue dashed 
line connects Lys188 to the structural zinc. 
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(i)  
 
(ii) 
 
Figure 2.5.3a (i-ii): HDX-MS heat maps with dimerized GSNOR. 
(i) GSNOR two second reaction data on dimerized structure. 
(ii) GSNOR four second reaction data on dimerized structure.  
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(iii) 
 
(iv) 
 
Figure 2.5.3a (iii-iv): HDX-MS heat maps with dimerized GSNOR. 
(iii)‘Back-side’ view of four second reaction data; 180⁰ horizontal rotation of (ii). Blue 
circles demonstrate location of allosteric GSNO binding. Blue dashed lines denote 
the distance between the α-carbon of Lys188 and the structural zinc. The distances 
are 24.4 Å for the left sided monomer and 23.2 Å for the right.  
(iv) Similar orientation of (iii), of the four second reaction data. GSNO is shown; blue 
dashed lines denote the distance between the α-carbon of Lys188 and the structural 
zinc, 22.0 Å.  
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2.6 Conclusion 
This chapter supports the existence of a possible allosteric site on the enzyme S-
nitrosoglutathione reductase (GSNOR). Experimental kinetic data provided a sigmoidal 
curve with a Hill coefficient (n) of 1.49 ± 0.037. This being greater than 1 suggests that the 
substrate S-nitrosoglutathione (GSNO) is binding in a cooperative manner. Molecular 
docking simulation on monomeric GSNOR presented a GSNOR binding site, located near 
the structural zinc. The amino acid residues Gly321, Lys323, Asn185, and Lys188 were 
implicated in the binding of GSNO at this site; peptides containing Gly321, Lys323, and 
Lys188 were successfully characterized by MS-MS. TRESI-HDX-MS studies were 
utilized to investigate this site further. Two and four second hydrogen to deuterium 
exchange reaction time points were observed. Under a two second HDX, the residues 
Gly321, Lys323, and Lys188 displayed a decrease of 1.4%, 1.4%, and 0.4%, respectively, 
after the addition of GSNO to the enzyme solution. This corresponds to a decrease in 
solvent exposure on the enzyme and supports the computational docking studies. Decreases 
were also observed around the active site, and NADH binding region. Under a four second 
HDX, the vast majority of peptides displayed an overall increase in deuterium uptake, in 
solvent exposure. This includes active site peptides and eludes to four seconds being too 
long to observe the interactions of GSNOR and GSNO.  
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2.7 Future Directions 
To further investigate the validity of the putative allosteric site, site directed 
mutagenesis on Lys323 and Lys188 is in progress. By mutating both Lys323 and Lys188 
to alanine, the loss of allosteric effects is hypothesized to be lost in the kinetic data. Other 
work includes successfully obtaining a third set of HDX-MS data of GNSOR + GSNO. As 
is, four sets of data were collected, with two sets being discarded due to discrepancies 
within the HDX GSNOR + GNSO spectra. One set was discarded due to notch failure of 
the TRESI device and thus improper mixing, leading to a dramatically reduced deuterium 
uptake observed. The second set of data discarded resulted in similar patterns, with very 
little deuterium uptake after the addition of GSNO despite the experimental conditions; the 
reasons for this has yet to be deduced. A third set is needed to have a complete triplicate 
data set.  
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APPENDIX 
 
APPENDIX A – Recombinant GSNOR 
Figure A.1: Recombinant wild type GSNOR protein sequence. 
Figure A.2: Recombinant GSNOR Plasmid Map. 
APPENDIX B – Mass Spectrometry: Native GSNOR 
Figure B.1: Native GSNOR MS Spectra. 
Table B1: Native GSNOR MS spectra peak m/z values and relative intensities. 
APPENDIX C – Mass Spectrometry: MS-MS GSNOR 
Figure C.1: GSNOR MS-MS Peptide Map. 
Table C.1: Full peptide list resulting from MS-MS identification. 
APPENDIX D – Mass Spectrometry: HDX-MS GSNOR 
Figure D.1: GSNOR MS fingerprint, with pepsin fragmentation. 
Figure D.2: GSNOR HDX-MS with two seconds reaction time. 
Figure D.3: GSNOR HDX-MS with four seconds reaction time. 
Figure D.4: GSNOR + 20x GSNO MS fingerprint, with pepsin fragmentation. 
Figure D.5: GSNOR + 20x GSNO HDX-MS with two seconds reaction time. 
Figure D.6: GSNOR + 20x GSNO HDX-MS with four seconds reaction time. 
Table D.1: Representative peptide to visualize deuterium uptake. 
Table D.2: Deuterium uptake results of two second reaction time. 
Table D.3: Deuterium uptake results of four second reaction time. 
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APPENDIX A – Recombinant GSNOR 
 
  1 10 20 
MGSSHHHHHH SSGLVPRGSH MANEVIKCKA AVAWEAGKPL 
 
30 40 50 60 
SIEEIEVAPP KAHEVRIKIIA TAVCHTDAY TLSGADPEGC 
 
70 80 90 100 
FPVILGHEGA GIVESVGEGV TKLKAGDTVI PLYIPQCGEC 
 
110 120 130 140 
KFCLNPKTNL CQKIRVTQGK GLMPDGTSRF TCKGKTILHY 
 
150 160 170 180 
MGTSTFSEYT VVADISVAKI DPLAPLDKVC LLGCGISTGY 
 
190 200 210 220 
GAAVNTAKLE PGSVCAVFGL GGVGLAVIMG CKVAGASRII 
 
230 240 250 260 
GVDINKDKFA RAKEFGATEC INPQDFSKPI QEVLIEMTDG 
 
270 280 290 300 
GVDYSFECIG NVKVMRAALE ACHKGWGVSV VVGVAASGEE 
 
310 320 330 340 
IATRPFQLVT GRTWKGTAFG GWKSVESVPK LVSEYMSKKI 
 
250 360 370          374 
KVDEFVTHNL SFDEINKAFE LMHSGKSIRT VVKI 
    
LEHHHHHH    
 
Figure A.1: Recombinant wild type GSNOR protein sequence. Amino acids are 
numbered from Met1 to Ile374, excluding the added histidine-tag (italicized). 
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Figure A.2: Recombinant GSNOR Plasmid Map. 
The following was designed and performed by Dr Bei Sun.96 
Human ADH5 was purchased from Origene (SC119755) and sub-cloned into the 
bacterial expression vector pET28b using Cold Fusion Cloning Kit (MJS BioLynx Inc. 
SYMC010A1). The following primers for PCR were designed according to manufacturer’s 
guidelines: 
Forward 5’ –GTGCCGCGCGGCAGCCATATGGCGAACGAGGTTATCAAG– 3’ 
Reverse 5’ –GTGGTGGTGGTGGTGCTCGAGAATCTTTACAACAGTTCGAATG– 3’ 
Colonies were screened using diagnostic restriction enzyme digest and by partial 
sequencing (Robart’s Research Institute, London Regional Genomics Center, London, 
Ontario, Canada). The final recombinant GSNOR contains a 6X-histidine tag at each 
terminus.  
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APPENDIX B – Mass Spectrometry: Native GSNOR 
 
Figure B.1: Native GSNOR MS Spectra. Peaks shown in the 3000-6000 m/z window. 
Three broad monomer peaks followed by dimerized GSNOR. 
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Figure B.1 continued, 
(1) – (3) Tertiary (3⁰) GSNOR, corresponding to monomer detection. 
(4) – (7) Quaternary (4⁰) GSNOR, corresponding to dimerized GSNOR.  
Table B1: Native GSNOR MS spectra peak m/z values and relative intensities. 
Figure labels as per Figure B.1. 
Peak Label m/z Relative Intensity 
(1) 
 
(2) 
 
(3) 
3098.6168 3.94 
3337.0012 18.17 
3619.1516 12.55 
(4) 
4107.7135 8.53 
4139.0778 8.13 
4168.3220 0.81 
(5) 
4313.2573 53.51 
4346.3899 57.04 
4380.1287 19.53 
(6) 
4543.0849 81.58 
4579.0460 100.00 
4609.1482 51.71 
(7) 
4798.6105 45.83 
4833.7635 62.79 
4865.8180 47.55 
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APPENDIX C – Mass Spectrometry: MS-MS GSNOR 
 
  1 10 20 
MGSSHHHHHH SSGLVPRGSH MANEVIKCKA AVAWEAGKPL 
 
30 40 50 60 
SIEEIEVAPP KAHEVRIKIIA TAVCHTDAY TLSGADPEGC 
 
70 80 90 100 
FPVILGHEGA GIVESVGEGV TKLKAGDTVI PLYIPQCGEC 
 
110 120 130 140 
KFCLNPKTNL CQKIRVTQGK GLMPDGTSRF TCKGKTILHY 
 
150 160 170 180 
MGTSTFSEYT VVADISVAKI DPLAPLDKVC LLGCGISTGY 
 
190 200 210 220 
GAAVNTAKLE PGSVCAVFGL GGVGLAVIMG CKVAGASRII 
 
230 240 250 260 
GVDINKDKFA RAKEFGATEC INPQDFSKPI QEVLIEMTDG 
 
270 280 290 300 
GVDYSFECIG NVKVMRAALE ACHKGWGVSV VVGVAASGEE 
 
310 320 330 340 
IATRPFQLVT GRTWKGTAFG GWKSVESVPK LVSEYMSKKI 
 
250 360 370          374 
KVDEFVTHNL SFDEINKAFE LMHSGKSIRT VVKI 
    
LEHHHHHH    
 
Figure C.1: GSNOR MS-MS Peptide Map. Highlighted amino acids are represented by 
identified peptides.  
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Table C.1: Full peptide list resulting from MS-MS identification. Theoretical amino 
acid number corresponds to labels beginning at Met1, whereas experimental amino acid 
numbers include the His tags of the recombinant protein. 292 total amino acids have been 
sequenced, however only 188 unique amino acids have coverage, resulting in a 52% 
sequence coverage of the 374 relevant residues. 48% coverage with His tags included.  
m/z 
Theoretical 
Amino Acid 
Number 
Experimental 
Amino Acid 
Number 
Amino Acid Sequence 
813.3543 0-6 20-26 (S)HMANEVI(K) 
690.0621 7-11 27-33 (I)KCKAAVA/(W) 
621.4647 11-22 31-42 (A)/AVAWEAGKPLSI(E) 
545.9043 25-43 45-54 (E)/IEVAPPKAHE/(V) 
406.9651 35-41 55-61 (E)/VRIKIIA/(T) 
457.5103 35-42 55-62 (E)/VRIKIIAT(A) 
508.7969 42-56 62-76 (A)/TAVCHTDAYTLSGAD(P) 
462.4796 52-56 72-76 (T)LSGAD(P) 
762.2355 64-79 84-99 (V)ILGHEGAGIVESVGEG(V) 
749.1952 66-81 86-101 (L)/GHEGAGIVESVGEGVT(K) 
1260.826 75-87 95-107 (E)/SVGEGVTKLKAGD(T) 
1017.545 78-87 98-107 (G)EGVTKLKAGD(T) 
889.3751 91-98 111-118 (I)PLYIPQCG(E) 
863.8682 131-138 151-158 (F)/TCKGKTIL/(H) 
796.6921 139-145 159-165 (L)/HYMGTST(F) 
903.3278 187-195 207-215 (T)AKLEPGSVC(A) 
646.5185 190-203 210-223 (L)/EPGSVCAVFGLGGV(G) 
1091.721 194-205 214-225 (S)VCAVFGLGGVGL/(A) 
1074.582 210-220 230-240 (M)GCKVAGASRII(G) 
537.7998 211-221 231-241 (G)CKVAGASRIIG(V) 
950.457 223-230 243-250 (V)DINKDKFA/(R) 
1053.654 228-236 248-256 (D)KFARAKEFG(A) 
669.6493 231-242 251-262 (A)/RAKEFGATECIN(P) 
726.2026 233-246 253-265 (A)/KEFGATECINPQD(F) 
818.1564 239-245 259-265 (T)ECINPQD(F) 
1061.054 246-254 266-274 (D)FSKPIQEVL/(I) 
1038.94 315-324 335-344 (W)/KGTAFGGWKS(V) 
1173.876 320-330 340-350 (F)/GGWKSVESVPK(L) 
587.3912 324-334 344-354 (K)SVESVPKLVSE/(Y) 
1241.154 334-343 354-363 (S)EYMSKKIKVD(E) 
965.4494 353-360 373-380 (F)/DEINKAFE/(L) 
1231.957 354-363 374-383 (D)EINKAFELMH(S) 
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APPENDIX D – Mass Spectrometry: HDX-MS GSNOR 
 
Figure D.1: GSNOR MS fingerprint, with pepsin fragmentation.  
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Figure D.2: GSNOR HDX-MS with two seconds reaction time. 
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Figure D.3: GSNOR HDX-MS with four seconds reaction time. 
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Figure D.4: GSNOR + 20x GSNO MS fingerprint, with pepsin fragmentation. 
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Figure D.5: GSNOR + 20x GSNO HDX-MS with two seconds reaction time. 
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Figure D.6: GSNOR + 20x GSNO HDX-MS with four seconds reaction time.  
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Table D.1: Representative peptide to visualize deuterium uptake.  
Peak information: 889.6 m/z, and the amino acid sequence is (I)PLYIPQCG(E) of residues 91-98. 
Deuterium uptake (D) and change of deuterium uptake (ΔD) is displayed. 
GSNOR HDX-MS: GSNOR + GSNO HDX-MS: 
No 
Deuterium 
Exchange  
 
No 
Deuterium 
Exchange 
 
Two sec 
Exchange 
D: 24.4% 
± 2.1 
Two sec 
Exchange 
D: 24.0%  
± 0.3 
 
ΔD: -0.4% 
Four sec 
Exchange 
D: 27.1% 
± 1.6 
Four sec 
Exchange 
D: 27.5%  
± 0.5 
 
ΔD: +0.4% 
16ul/min acid, 2ul/min GSNOR
m/z
890 892 894
%
0
100
m/z
890 892 894
%
0
100
m/z
890 892 894
%
0
100
2017_10_19 (1) 31 (2.609) Cm (2:52)
8.12e3889.6196
890.6340
891.6270
892.6313
2017_10_19 5MM (1) 2 (0.184) Cm (2:59)
3.66e3890.8105
889.7850
891.8035
892.8192
893.8132
2017_10_19 10MM (1) 12 (1.020) Cm (2:55)
4.95e3890.8656
889.8622
891.8807
892.8854
893.7580
16ul/min acid, 2ul/min GSNOR 
m/z
890 892 894
%
0
100
m/z
890 892 894
%
0
100
m/z
890 892 894
%
0
100
2017_10_19 GSNO (1) 28 (2.359) Cm (2:59)
5.25e3889.8953
890.9098
891.9028 892.8854
893.8796
2017_10_19 GSNO 5MM (1) 32 (2.693) Cm (2:59)
3.77e3890.9098
889.9063
891.9028
892.9185
893.9237
2017_10_19 GSNO 10MM (1) 51 (4.282) Cm (2:59)
2.97e3890.8877
889.8843
891.9028
892.9075
893.9016
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Table D.2: Deuterium uptake results of two second reaction time. With and without 
the addition of substrate GSNO. The difference in those values is shown as a heat map, 
Red = decrease in deuterium uptake, Blue = increase in uptake. The colour legend used 
for crystal structure representation images is shown below. 
Red Salmon Pink  Sky Blue  Blue 
-1.8 -0.7 -0.4 0   0.6 3.4 
 
Baseline 
Deuterium 
Uptake 
(%) (n=6) 
GSNO 
Deuterium 
Uptake 
(%) (n=2) 
Δ Uptake 
(%) & 
Colour 
Amino 
Acid 
Residue 
Amino Acid Sequence 
17.2 ± 1.4 17.0 ± 0.0 -0.2 Pink 0-6 (S)HMANEVI(K) 
15.9 ± 2.7 15.8 ± 1.2 -0.1 Pink 7-11 (I)KCKAAVA/(W) 
12.7 ± 1.1 12.8 ± 1.2 +0.2 Sky 11-22 (A)/AVAWEAGKPLSI(E)  
17.0 ± 1.2 16.7 ± 0.7 -0.3 Pink 25-34 (E)/IEVAPPKAHE/(V) 
21.3 ± 1.6 20.7 ± 0.0 -0.6 Salmon 35-41 (E)/VRIKIIA/(T) 
21.6 ± 1.5 20.2 ± 0.5 -1.4 Red 35-42 (E)/VRIKIIAT(A) 
11.9 ± 1.1 11.5 ± 0.5  -0.4 Pink 42-56 (A)/TAVCHTDAYTLSGAD(P) 
20.3 ± 2.1 19.2 ± 0.5 -1.2 Red 52-56 (T)LSGAD(P)  
9.5 ± 0.9 9.2 ± 0.2 -0.3 Pink 64-79 (V)ILGHEGAGIVESVGEG(V) 
9.7 ± 0.7 9.0 ± 1.0 -0.7 Salmon 66-81 (L)/GHEGAGIVESVGEGVT(K) 
18.4 ± 2.5 20.8 ± 1.2 +2.4 Blue 78-87 (G)EGVTKLKAGD(T) 
24.4 ± 2.1 24.0 ± 0.3 -0.4 Pink 91-98 (I)PLYIPQCG(E) 
15.7 ± 1.3 15.3 ± 0.0 -0.3 Pink 131-138 (F)/TCKGKTIL/(H) 
16.8 ± 1.7 17.0 ± 0.0 +0.3 Sky 139-145 (L)/HYMGTST(F) 
25.7 ± 2.8 25.3 ± 0.0 -0.4 Pink 187-195 (T)AKLEPGSVC(A) 
19.3 ± 1.6 18.3 ± 1.0 -0.9 Red 190-203 (L)/EPGSVCAVFGLGGV(G) 
9.3 ± 0.7 9.0 ± 1.3 -0.3 Pink 194-205 (S)VCAVFGLGGVGL/(A) 
16.8 ± 2.5 15.0 ± 0.0 -1.8 Red 210-220 (M)GCKVAGASRII(G) 
15.1 ± 1.2 15.3 ± 0.0 +0.2 Sky 223-230 (V)DINKDKFA/(R) 
13.4 ± 1.4 12.7 ± 0.7 -0.7 Salmon 228-236 (D)KFARAKEFG(A) 
13.8 ± 0.5 15.7 ± 0.0 +1.8 Blue 231-242 (A)/RAKEFGATECIN(P) 
19.9 ± 2.3 23.3 ± 0.0 +3.4 Blue 233-245 (A)/KEFGATECINPQD(F) 
29.5 ± 3.5 29.7 ± 0.0 +0.1 Sky 239-245 (T)ECINPQD(F) 
17.1 ± 1.8 15.8 ± 1.2 -1.2 Red 246-254 (D)FSKPIQEVL/(I)  
15.9 ± 2.5 15.0 ± 1.0 -0.9 Red 315-324 (W)/KGTAFGGWKS(V) 
13.7 ± 1.3 12.3 ± 0.3 -1.4 Red 320-330 (F)/GGWKSVESVPK(L) 
14.8 ± 1.3 14.3 ± 0.3 -0.4 Pink 324-334 (K)SVESVPKLVSE/(Y) 
15.0 ± 1.1 15.3 ± 0.0 +0.3 Sky 334-343 (S)EYMSKKIKVD(E) 
19.3 ± 1.3 19.0 ± 0.7 -0.3 Pink 353-360 (F)/DEINKAFE/(L) 
17.6 ± 1.4 18.2 ± 0.2 +0.6 Sky 354-363 (D)EINKAFELMH(S) 
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Table D.3: Deuterium uptake results of four second reaction time. With and without 
the addition of substrate GSNO. The difference in those values is shown as a heat map, 
Red = decrease in deuterium uptake, Blue = increase in uptake. The colour legend used 
for crystal structure representation images is shown below. 
Red Salmon  Sky Blue Dodger Blue  Blue 
-5.2 -0.8 0 0.7 1.4 5.1 
 
Baseline 
Deuterium 
Uptake 
(%) (n=6) 
GSNO 
Deuterium 
Uptake 
(%) (n=2) 
Δ Uptake 
(%) & 
Colour 
Amino 
Acid 
Residue 
Amino Acid Sequence 
16.6 ± 1.8 18.7 ± 0.0 +2.1 Blue 0-6 (S)HMANEVI(K) 
16.4 ± 3.1 17.7 ± 0.7 +1.3 Dodger 7-11 (I)KCKAAVA/(W) 
12.3 ± 1.9 13.2 ± 0.2 +0.8 Dodger 11-22 (A)/AVAWEAGKPLSI(E)  
16.5 ± 2.3 17.7 ± 0.0 +1.2 Dodger 25-34 (E)/IEVAPPKAHE/(V) 
20.3 ± 3.1 21.7 ± 0.0 +1.4 Dodger 35-41 (E)/VRIKIIA/(T) 
20.4 ± 2.4 21.2 ± 0.5 +0.8 Dodger 35-42 (E)/VRIKIIAT(A) 
11.7 ± 2.0 12.2 ± 0.2 +0.5 Sky 42-56 (A)/TAVCHTDAYTLSGAD(P) 
20.9 ± 2.5 21.5 ± 0.5 +0.6 Sky 52-56 (T)LSGAD(P)  
9.3 ± 1.3 10.0 ± 0.0 +0.7 Sky 64-79 (V)ILGHEGAGIVESVGEG(V) 
9.2 ± 1.4 9.5 ± 0.5 +0.3 Sky 66-81 (L)/GHEGAGIVESVGEGVT(K) 
19.2 ± 3.7 23.5 ± 3.5 +4.3 Blue  78-87 (G)EGVTKLKAGD(T) 
27.1 ± 1.6 27.5 ± 0.5 +0.4 Sky 91-98 (I)PLYIPQCG(E) 
15.3 ± 2.3 16.0 ± 0.0 +0.7 Sky 131-138 (F)/TCKGKTIL/(H) 
17.3 ± 2.7 17.7 ± 0.0 +0.3 Sky 139-145 (L)/HYMGTST(F) 
24.9 ± 2.7 24.3 ± 0.0 -0.6 Salmon 187-195 (T)AKLEPGSVC(A) 
19.3 ± 2.4 18.5 ± 1.8 -0.8 Salmon 190-203 (L)/EPGSVCAVFGLGGV(G) 
8.8 ± 1.2 9.7 ± 0.7 +0.9 Dodger 194-205 (S)VCAVFGLGGVGL/(A) 
17.7 ± 2.3 13.7 ± 0.0 -4.0 Red 210-220 (M)GCKVAGASRII(G) 
14.3 ± 2.4 16.3 ± 0.3 +2.1 Blue 223-230 (V)DINKDKFA/(R) 
13.1 ± 2.4 13.2 ± 0.2 +0.1 Sky 228-236 (D)KFARAKEFG(A) 
11.0 ± 0.3 14.7 ± 0.0 +3.7 Blue 231-242 (A)/RAKEFGATECIN(P) 
18.6 ± 4.0 23.7 ± 0.0 +5.1 Blue 233-245 (A)/KEFGATECINPQD(F) 
30.1 ± 2.9 30.7 ± 0.0 +0.6 Sky  239-245 (T)ECINPQD(F) 
17.4 ± 2.3 12.2 ± 3.8 -5.2 Red 246-254 (D)FSKPIQEVL/(I)  
15.8 ± 3.6 15.8 ± 0.2 +0.1 Sky 315-324 (W)/KGTAFGGWKS(V) 
13.0 ± 2.0 13.5 ± 0.2 +0.5 Sky 320-330 (F)/GGWKSVESVPK(L) 
14.5 ± 1.6 15.3 ± 0.3 +0.8 Dodger 324-334 (K)SVESVPKLVSE/(Y) 
15.7 ± 2.2 15.3 ± 0.0 -0.3 Salmon 334-343 (S)EYMSKKIKVD(E) 
17.5 ± 2.8 19.7 ± 0.3 +2.2 Blue 353-360 (F)/DEINKAFE/(L) 
17.2 ± 2.8 18.2 ± 0.5 +1.0 Dodger 354-363 (D)EINKAFELMH(S) 
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